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An updated model of the GABA(A) benzodiazepine receptor pharmacophore of the 𝛼5-BzR/GABA(A) subtype has been
constructed prompted by the synthesis of subtype selective ligands in light of the recent developments in both ligand synthesis,
behavioral studies, and molecular modeling studies of the binding site itself. A number of BzR/GABA(A) 𝛼5 subtype selective
compounds were synthesized, notably 𝛼5-subtype selective inverse agonist PWZ-029 (1) which is active in enhancing cognition
in both rodents and primates. In addition, a chiral positive allosteric modulator (PAM), SH-053-2󸀠F-R-CH
3
(2), has been shown
to reverse the deleterious effects in the MAM-model of schizophrenia as well as alleviate constriction in airway smooth muscle.
Presented here is an updated model of the pharmacophore for 𝛼5𝛽2𝛾2 Bz/GABA(A) receptors, including a rendering of PWZ-
029 docked within the 𝛼5-binding pocket showing specific interactions of the molecule with the receptor. Differences in the
included volume as compared to 𝛼1𝛽2𝛾2, 𝛼2𝛽2𝛾2, and 𝛼3𝛽2𝛾2 will be illustrated for clarity. These new models enhance the ability
to understand structural characteristics of ligands which act as agonists, antagonists, or inverse agonists at the Bz BS of GABA(A)
receptors.
1. Introduction
Thegamma-amino butyric acid A (GABAA) receptor is a het-
eropentameric chloride ion channel.This channel is generally
made up of two 𝛼-subunits, two 𝛽-subunits, and a single 𝛾-
subunit arranged in an 𝛼𝛽𝛼𝛽𝛾 fashion.TheGABAA receptors
(GABAAR) are responsible for a myriad of brain functions.
Positive allosteric modulators (PAMs) and negative allosteric
modulators (NAMs) act on the benzodiazepine (BZ) site of
the GABAAR which can change the conformation of the
receptor to inhibit or excite the neurons associated with the
ion channel. To date, researchers have been unable to get
an X-ray crystal structure of a functional Bz/GABAAR ion
channel. Recently, Miller and Aricescu [1] have reported the
crystal structure of a homopentameric GABAAR containing
the𝛽3-subunit at 3 A˚ resolution. Although this work provides
great promise that other heteropentameric GABAARs will
be crystallized in the near future, molecular modeling and
structure-activity-relationships (SARs) still remain key tools
to find better subtype-selective binding agents.
2. Subtype Selective Ligands for 𝛼5
GABA(A)/Bz Receptors
Interest in BzR/GABA(A) 𝛼5 subtypes began years ago when
it was realized that 𝛼5𝛽3𝛾2 Bz/GABA(A) subtypes are located
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Figure 1: Alpha 5 selective compounds [13]. This figure is modified from that reported in [13].
primarily in the hippocampus. More recently this interest has
been confirmed by the report of Mo¨hler et al. [2–5] on 𝛼5
“knock-in mice.” This group has provided strong evidence
that hippocampal extrasynaptic 𝛼5 GABA(A) receptors play
a critical role in associative learning as mentioned above [6–
11].
Earlier we synthesized a series of 𝛼5 subtype selective
ligands (RY-023, RY-024, RY-079, and RY-080) based on the
structure of Ro 15-4513 and reported their binding affinity [6],
as well as several ligands by Atack et al. [12]. These ligands
are benzodiazepine receptor (BzR) negative modulators in
vivo and a number of these compounds have been shown to
enhance memory and learning [13]. One of these ligands was
shown by Bailey et al. [6] to be important in the acquisition of
fear conditioning and has provided further evidence for the
involvement of hippocampal GABA(A)/BzR in learning and
anxiety [13]. This is in agreement with the work of DeLorey
et al. [7] in a memory model with a ligand closely related
to 𝛼5 subtype selective inverse agonists RY-024 and RY-079
including PWZ-029 (1).
In order to enhance the𝛼5 subtype selectivity, the bivalent
form of RY-80 (3) was prepared to provide XLi-093 (4)
[13]. The binding affinity of XLi-093 in vitro was determined
on 𝛼
1–6𝛽3𝛾2 LTK cells and is illustrated in Figure 1. This
bivalent ligand exhibited little or no affinity at 𝛼
1–4,6𝛽3𝛾2
BzR/GABA(A) subtypes, but this 𝛼5 ligand had a𝐾
𝑖
of 15 nM
at the 𝛼5𝛽3𝛾2 subtype [14]. Since this receptor binding study
indicated bivalent ligandXLi-093 bound almost exclusively to
the 𝛼5 subtype, the efficacy of this ligand onGABA(A) recep-
tor subtypes expressed in Xenopus oocytes was investigated
by Sieghart, Furtmueller, Li, and Cook [14, 15]. Analysis of the
data indicated that XLi-093 up to a concentration of 1𝜇Mdid
not trigger chloride flux in any one of the GABA(A) subtypes
tested. At 1 𝜇M XLi-093 did not modulate GABA induced
chloride flux in 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, or 𝛼3𝛽3𝛾2 receptors, but
very slightly inhibited chloride flux in 𝛼5𝛽3𝛾2 subtypes. At
1 𝜇M, XLi-093 barely influenced benzodiazepine (Valium)
stimulation of GABA-induced current in 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
Figure 2: XLi-093 (4) aligned in the included volume of the phar-
macophore receptor model for the 𝛼5𝛽3𝛾2 subtype [17, 18] (this
figure is modified from the figure in Clayton et al., 2007) [23].
and 𝛼3𝛽3𝛾2 BzR but shifted the diazepam dose response
curve to the right in 𝛼5𝛽3𝛾2 receptors in a very signifi-
cant manner [16]. Importantly, bivalent ligand XLi-093 was
able to dose dependently and completely inhibit diazepam-
stimulated currents in 𝛼5𝛽3𝛾2 receptors. This was the first
subtype selective benzodiazepine receptor site antagonist at
𝛼5 receptors. This bivalent ligand XLi-093 provided a lead
compound for all of the bivalent ligands in this research [16].
Illustrated in Figure 2 is XLi-093 (4) aligned excellently
within the pharmacophore-receptor model of the 𝛼5𝛽3𝛾2
subtype [14, 16–19]. The fit to the pharmacophore-receptor
and the binding data indicate that bivalent ligands will bind
to BzR subtypes [14, 19]. It is believed that the dimer enters
the binding pocket with one monomeric unit docking while
the other monomer tethered by a linker extends out of
the protein into the extracellular domain. If this is in fact
true that the second imidazole unit is protruding into the
extracellular domain of the BzR/GABA(A) 𝛼5 binding site,
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Table 1: Full PDSP panel receptor binding reported (Roth [138]) for XLi-093 and XLi-356.
Cook code 5ht1a 5ht1b 5ht1d 5ht1e 5ht2a 5ht2b 5ht2c 5ht3 5ht5a 5ht6 5ht7 𝛼1A 𝛽1B 𝛼2A 𝛼2B
XLi093 ∗ Repeat ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Cook code 𝛼2C Beta1 Beta2 CB1 CB2 D1 D2 D3 D4 D5 DAT DOR H1 H2 H3
XLi093 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Cook code H4 Imidaz oline KOR M1 M2 M3 M4 M5 MDR MOR NET NMDA SERT 𝜎1 𝜎2
XLi093 ∗ ∗ 2,024.00 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ 6,118.00 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗




values are reported in nanomolar concentration, CaseWestern Reserve University. “∗” indicates “primarymissed”
(<50% inhibition at 10 𝜇M). See full data of the PDSP screen in the report of Clayton [22].
it could have a profound effect on the ligand design. This
means other homodimers or even heterodimers may bind to
BzR/GABA(A)ergic sites.
In this vein, Wenger, Li, and Cook et al. [13, 20, 21] earlier
described preliminary data that XLi-093, an 𝛼5 subtype
selective antagonist, enhances performance of C57BL/6Jmice
under a titrating delayed matching to position schedule of
cognition, as illustrated in Figure 3 [14, 16–19].This indicates,
however, that this agent does cross the blood brain barrier.
Bivalent ligands have a preferred linker of 3–5 methylene
units, between the two pharmacophores (see XLi-093). This
was established by NMR experiments run at low tempera-
tures, X-ray crystallography, and molecular modeling of the
ligands in question and will be discussed [14, 17, 18].
Based on this data, additional 𝛼5-subtype selective lig-
ands have been prepared (see Figure 4). The basic imida-
zobenzodiazepine structure has been maintained [7]; how-
ever substituents were varied in regions around the scaffold
based on molecular modeling [6]. These are now the most
𝛼5 subtype selective ligands ever reported [22]. Moreover,
the ability to increase the subtype selectivity can be done
by selecting specific substituents on these ligands to new
agents with 400–1000-fold 𝛼5-selectivity over the remaining
5 subtypes.This is an important step forward to understanding
the true, unequivocal physiological responses mediated by
𝛼5 subtypes in regard to cognition (amnesia), schizophrenia,
anxiety, and convulsions, all of which in some degree are
influenced by 𝛼5 subtypes. Based on the ligands in Figures
4 and 5, affinity has occurred principally at 𝛼5 subtypes. In
addition, since XLi-093 bound very tightly only to 𝛼5 BzR
subtypes, the bivalent nature and functionality presented here
can be incorporated into other dimeric ligands.
As shown previously in Figure 3, 𝛼5-antagonist XLi-093
(4) was shown to enhance cognition. In another study, a
reduction of the two acetylenic groups of XLi-093 resulted
in ethyl groups [14], providing a new bivalent ligand (XLi-
356, 10) which shows 𝛼5-selective binding with very low
affinity for 𝛼1 subtypes (Figure 5). Efficacy (oocyte) data
shows XLi-356 is an 𝛼5 negative allosteric modulator [7, 13].
DeLorey et al. have recently shown in mice that XLi-356
does potently reverse scopolamine induced memory deficits
[7]. This bivalent 𝛼5 inverse agonist enhanced cognition
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Figure 3: XLi-093 (4) effects on cognition enhancement byWenger
et al. (data on statistical significance not shown, unpublished
results). Effects of 4 on cognition from the mean delay achieved by
C57BL/6J mice titrating delayed matching-to-position schedule.
in agreement with work reported from our laboratory on
monovalent inverse agonists RY-10 [6] and RY-23 [7].
The dimers XLi-093 (4) and XLi-356 (10) were sent to
Case Western Reserve (NIMH supported PDSP program,
Roth et al.) for full panel receptor binding and they do not
bind to other receptors at levels of concern (Table 1).
Although XLi-093 (4) was found to be an antagonist
at the 𝛼5 subtype, XLi-356 (10) was found to be a weak
agonist-antagonist. XLi-356 was found to reverse scopo-
lamine induced memory deficits in mice. When XLi-356
was looked at in audio cued fear conditioning, the results
show no activity. This suggests that the effect of XLi-356
is selective through 𝛼5 receptors which are abundant in
the hippocampus which is highly associated with contextual
memory. Audio cuedmemory instead is amygdala-based and
should not be affected by an 𝛼5 subtype selective compound
[39–42].
As illustrated in Figure 6, scopolamine (1mg/kg) reduced
freezing (i.e., impairs memory) generally due to coupling the




































































































aData shown here are the means of two determinations which differed by less than 10%. ND: not determined (presumably similar to 𝛼6).
indicate the 𝛼5 subtype selectivity.are binding datasets of PWZ-029b1a–c (1) from three separate laboratories. This figure is modified from that illustrated in reference [22] to




























































































Figure 5: Binding data of selected imidazobenzodiazepines substituted with an E-ring as compared to XLi-356 (10).


























Contextual memory Audio cued memory
XLi356 + scopolamine XLi356 10mg +
Figure 6: Visual and audio cued data for XLi-356 (10). This figure was modified from that in [22].
context (the cage) with a mild shock. XLi-356 (10mg/kg)
attenuated the impairment of memory returning the freezing
to the levels on par with subjects dosed with vehicle. In audio
cued memory the response was activated by sound, not the
context. XLi-356 was not able to reverse this type of memory
effect which is amygdala driven. A similar effect was observed
for XLi-093 by Harris et al. [43]. XLi-093 is the most selective
antagonist for 𝛼5 subtypes reported to date [13, 43] and is a
very useful 𝛼5 antagonist used by many in vivo [22, 44, 45].
Molecular modeling combined with this knowledge was
used to generate new lead compounds aimed at the develop-
ment of 𝛼5-subtype selective positive and negative allosteric
modulators to study cognition as well as amnesia mediated
by the hippocampus. All of these compounds have been pre-
pared based on the structure of current 𝛼5-subtype selective
ligands synthesized in Milwaukee [46] (see Figures 4 and 5),
as well as the binding affinity (15 nM)/selectivity of bivalent
𝛼5 antagonist XLi-093 (4) [13].
In efforts to enhance 𝛼5-selectivity in regards to cog-
nition, Cook, Bailey, and Helmstetter et al. have employed
RY-024 to study the hippocampal involvement in the ben-
zodiazepine receptor in learning and anxiety [14, 19]. Sup-
porting this Harris, DeLorey et al. show in mice that 𝛼5
NAMs (1) and RY-10 potently reversed scopolamine-induced
memory impairment. These 𝛼5 NAMs provide insight as to
how GABAARs influence contextual memory, an aspect of
memory affected in age associated memory impairment and
especially in Alzheimer’s disease [13, 62–64]. In addition,
Savic´ et al. have used the 𝛼1 preferring antagonist, BCCt,
in passive avoidance studies, in which midazolam’s amnesic
effects are shown to be due to interaction of agonist ligands at
𝛼5 in addition to 𝛼1𝛽3𝛾2 BzR subtypes [24, 65].
3. PWZ-029: A Negative Allosteric Modulator
PWZ-029 (1) has been studied extensively as an 𝛼5-GABAAR
inverse agonist and in certain experimental models has
Table 2: Affinity of PWZ-029 (1);𝐾
𝑖
(nM)a.
Code MW 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
PWZ-029 (1) 291.73 >300 >300 >300 ND 38.8 >300
PWZ-029 (1) 291.73 920 ND ND ND 30 ND
PWZ-029 (1) 291.73 362 180 328 ND 6 ND
aData from three separate laboratories.
been shown to enhance cognition. The binding data from
three separate laboratories (Table 2) have all shown that it
exhibits remarkable selectivity for the 𝛼5 subunit-containing
receptors, all greater than 60-fold compared to the next
subunit.
Electrophysiological efficacy testing done by Sieghart et
al. in oocytes demonstrated that PWZ-029 (1) acts as a
negative allosteric modulator at the 𝛼5-subunit, with a very
weak agonist activity at the 𝛼1, 𝛼2, and 𝛼3 subunits (Figure 7).
At a pharmacologically relevant concentration of 0.1 𝜇M,
PWZ-029 exhibits moderate negative modulation at the 𝛼5-
subunit, while showing little or no effect at the 𝛼1, 𝛼2, or 𝛼3-
subunits.
Milic´ et al. reported on the effects of PWZ-029 in the
widely used novel object recognition test, which differentiates
between the exploration time of novel and familiar objects.
As shown by significant differences between the exploration
times of the novel and familiar object (Figure 8(a)), as well
as the respective discrimination indices (Figure 8(b)), all the
three tested doses of PWZ-029 (2, 5 and 10mg/kg) improved
object recognition in rats after the 24 h delay period. Addi-
tionally, in the procedure with the 1 h delay between training
and testing, the lowest of the tested doses of PWZ-029
(2mg/kg) successfully reversed the deficit in recognition
memory induced by 0.3mg/kg scopolamine (Figure 9) [25].
The results of the described study showed for the first
time that inverse agonism at 𝛼5-GABAA receptors may
be efficacious in both improving cognitive performance in






































































































Figure 8: The effects of PWZ-029 (1) (2, 5 and 10mg/kg) on (a) time exploring familiar and novel objects and (b) discrimination indices in
the novel object recognition test using a 24 h delay (mean + SEM). Significant differences are indicated with asterisks (paired-samples 𝑡-test,
novel versus familiar, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001). A significant difference from zero is indicated with hashes (one sample 𝑡-test,
##
𝑝 < 0.01). The number of animals per each treatment group was 10. SOL = solvent [25].





















































































































Figure 9:The effects of 0.3mg/kg scopolamine (SCOP 0.3) and combination of 0.3mg/kg scopolamine and PWZ-029 (1) (2, 5, and 10mg/kg)
on the rats’ performance in the object recognition task after a 1 h delay: (a) time exploring familiar and novel objects and (b) discrimination
index. Data are represented as mean + SEM. Significant differences are indicated with asterisks (paired-samples 𝑡-test, novel versus familiar,
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01). A significant difference from zero is indicated with hashes (one sample 𝑡-test, #𝑝 < 0.05). The number of animals per
each treatment group was 12–15. SAL = saline, SOL = solvent [25].
unimpaired subjects and ameliorating cognitive deficits in
pharmacologically impaired subjects, as assessed in two
protocols of the same animal model [25].
In a recent byRowlett et al. [26], negative allostericmodu-
lator PWZ-029 was evaluated in female rhesus monkeys (𝑛 =
4) in an Object Retrieval test with Detours (ORD; Figure 10
for details). 1 was administered via i.v. catheters in ORD
trained monkeys and evaluated for cognition enhancement.
A successful trial was determined by the ability of the
subject to obtain a food reward within a transparent box
with a single open side, with varying degrees of difficulty
(“easy” or “difficult” or “mixed” as a combination of both)
based on food placement within the box. In “mixed” trials
using PWZ-029, no significant results were observed when
compared to vehicle (Figure 11(a)). “Difficult” trials, however,
exhibited an increasing dose-dependent curve for successful
trials (Figure 11(b)). These results were attenuated by a coad-
ministration 𝛼5-antagonist XLi-093 (Figure 11(c)). PWZ-029
was also shown to dose-dependently reverse the cholinergic
deficits that were induced by scopolamine (Figure 11(d)) [26].
These findings suggest that PWZ-029 can enhance per-
formance on the ORD task, only under conditions in which
baseline performance is attenuated. The effects of PWZ-
029 were antagonized in a surmountable fashion by the
selective 𝛼5-GABAA ligand, XLi-093, consistent with PWZ-
029’s effects beingmediating via the 𝛼5-GABAA receptor.The
results are consistent with the view that 𝛼5 GABAA receptors
may represent a viable target for discovery of cognitive
enhancing agents.
In addition, we have newdata showing thatmodulation of
𝛼5-GABAARs by PWZ-029 rescues Hip-dependent memory
in an AD rat model [PMID: 23634826] as evidenced by
a significant decrease in the latency to reach the hidden
platform (memory probe trials) on spatial water maze task
(Figure 12). Roche has employed a similar strategy at 𝛼5
subtypes and recently has a drug in the clinic to treat
symptoms of dementia in Down syndrome patients. It is well
known many Down syndrome patients develop Alzheimer’s
disease or a dementia with a very similar etiology. This is
aimed at treating early onset Alzheimer’s patients.
4. PWZ-029 Docking within 𝛼5𝛾2 GABAA
Receptor Subunit Homology Model
These studies with PWZ-029 led to the molecular model
rendering of the compound docked within the 𝛼5𝛾2 BzR
subtype (Figures 13–16).Themodel figures have the following
features:
The docking of PWZ-029 within the GABAA/BzR shows
the molecule bound and interacting with specific amino
acids. The A and B rings of the benzodiazepine framework
undergo a 𝜋-stacking interaction with HIS 105, indicated
by the magenta coloring. At the other end of the molecule
the methoxy lone pair and imidazole nitrogen lone pair act
as a hydrogen bond acceptors with THR 210 and TYR 213,
respectively. These interactions are shown by the aqua-blue
descriptors.
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Methods
Subjects:
ORD task examples of different types of trials
Easy-right outside Easy-right inside Difficult-right deep





































































































Rhesus monkeys (Macaca mulatta)
N = 5
Implanted with chronic i.v. catheters
Procedure:
Object retrieval with detours (ORD)
15 trials per session
Easy, difficult, and mixed trials (see diagram)
Tests:
(i) PWZ-029 · mixed trials
(ii) PWZ-029 · difficult trials
(iv) Scopolamine · mixed trials
(v) PWZ-029 + scopolamine · mixed trials
Measurements: % correct trials—trial in which
food is obtained with the first reach
Errors: barrier reaches (hand in contact with closed
side of box) and incomplete trials (food grasped but
dropped)
(iii) PWZ-029 + XLi-093 · difficult trials
Figure 10: ORD methods and procedure [26].
5. Subtype Selective Agonists for
𝛼5 GABAA/Bz Receptors
Mo¨hler has proposed that 𝛼5 selective inverse agonists or
𝛼5 selective agonists might enhance cognition [5, 13, 16–
18, 86]. This is because of the extrasynaptic pyramidal nature
of 𝛼5𝛽3𝛾2 subtypes, located almost exclusively in the hip-
pocampus. Because of this, a new “potential agonist” which
binds solely to 𝛼5𝛽3𝛾2 subtypes was designed by computer
modeling (see Figure 17). This ligand (DM-I-81, 9) has an
agonist framework and binds only to 𝛼5𝛽3𝛾2 subtypes [13,
17, 18, 86]. The binding potency at 𝛼5 subtypes is 176 nM.
Although the 8-pendant phenyl of DM-I-81 was lipophilic
and bound to the 𝐿
2
pocket, additional work on the 8-
position of this scaffold has been abandoned and generally
left as an acetylene or halide function, with a few exceptions.
The steric bulk of the 8-phenyl moiety was felt detrimental to
activity and potency which may have led to the weak binding
affinity.
6. Alpha 5 Positive Allosteric
Modulators in Schizophrenia
In addition to inverse agonists, a number of other 𝛼5-
GABAAR positive allosteric modulators (PAMs) have been
synthesized. These compounds, such as SH-053-2󸀠F-R-CH
3
(2), have been shown to decrease the firing rate of synapses
controlling cognition and can be used to treat schizophrenia.
The following is reported by Gill, Cook, and Grace et al.
[27–38].
There are a number of novel benzodiazepine-positive
allosteric modulators (PAMs), selective for the 𝛼5 subunit




which has been tested for its ability to effect the out-
put of the HPC (hippocampal) in methylazoxymethanol-
(MAM-) treated animals, which can lead to hyperactivity
in the dopamine system [27–38]. In addition, the effect of
this compounds (2) response to amphetamine in MAM-
animals on the hyperactive locomotor activity was exam-
ined. Schizophrenic-like symptoms can be induced into
rats when treated prenatally with DNA-methylating agent,
methylazoxymethanol, on gestational day (GD) 17. These
neurochemical outcomes and changes in behavior mimic
those found in schizophrenic patients. Systemic treatment
with (2) resulted in a reduced number of spontaneously active
DA (dopamine) neurons in the VTA (ventral tegmental area)
of MAM animals (Figure 18) to levels seen in animals treated
with vehicle (i.e., saline). To confirm the location of action,
2 was also directly infused into the ventral HPC (Figure 19)
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(d) Reversal of scopolamine deficit
Figure 11: Cognitive-enhancing effects of PWZ-029 in the rhesus monkey Object Retrieval with Detours (ORD) task (𝑛 = 5 monkeys). (a)
Effects of PWZ-029 on ORD tests consist of both easy and difficult trials: (b) PWZ-029 enhanced performance on the ORD task when tested
with difficult trials only; (c) enhancement of ORD performance by 0.018mg/kg of PWZ-029 was attenuated by the 𝛼5 GABAA-preferring
antagonist XLi-093 and this antagonism was surmountable by increasing the PWZ-029 dose; (d) PWZ-029 reversed performance impaired
by 0.01mg/kg of scopolamine [26]. ∗𝑝 < 0.05 versus vehicle, ∗∗𝑝 < 0.05 versus Scopolamine.
and was shown to have the same effect. Moreover, HPC
neurons in both SAL and MAM animals showed diminished
cortical-evoked responses following𝛼5-GABAARPAM treat-
ment. This study is important for it supports a treatment
of schizophrenia that targets abnormal HPC output, which
in turn normalized dopaminergic neuronal activity [27–38].
This is a novel approach to treat schizophrenia.
The pathophysiology of schizophrenia has identified
hippocampal (HPC) dysfunction as a major mediator as
reported by many including Anthony Grace [27–38]. This
included morphological changes, reduced HPC volume, and
GAD67 expression [27, 28] that have been reported after
death in the brains of patients with schizophrenia. Both HPC
activation andmorphology changes have been identified that
can precede psychotic symptoms or correlate with severity of
cognitive deficits [29–33].This has been shown in a cognitive
test during baseline and activation.
Many animal models of schizophrenia were essential to
behavioral pathology and have delivered new knowledge
about the network disturbances that contribute to CNS
disorder.This study shows that the offspring ofMAM-treated
animals showed both structural and behavioral abnormali-
ties. These were consistent with those observed in patients
with schizophrenia. The animals had reduced limbic cortical
and HPC volumes with increased cell packing density and
showed increased sensitivity to psychostimulants [34–36].
In addition, the startle response in prepulse inhibition was
reduced in MAM-treated animals and deficits in latent
inhibition were observed [35]. Furthermore, a pathological
rise in spontaneous dopamine (DA) activity by the ventral
tegmental area (VTA) was observed that can be attributed
to aberrant activation within the ventral HPC [36]. It was
suggested that reductions in parvalbumin- (PV-) stained
interneurons might be the reason for the hyperactivation of
the HPC and disruption of normal oscillatory activity in the
HPC and cortex of MAM animals [38, 61]. At least this is
the prevailing hypothesis at the moment put forth by many
investigators (see references cited in [27–38]).
Selective 𝛼5-GABAAR positive allosteric modulator (2)
was successful in reversing the pathological increase in tonic
DA transmission in methylazoxymethanol rats by targeting
abnormal hippocampal activity. In addition, the 𝛼5-PAMwas





















Figure 12: PWZ-029 rescues spatial memory deficits in AD model
as evidenced by a decrease in the latency to reach the hidden
platform (probe test) in the water maze relative to vehicle (VEH,
∗
𝑝 < 0.05).








Figure 15: PWZ-029 docked with A.A. residue interactions.
4.09
Figure 16: PWZ-029 docked with interactions. (1) HIS 105 𝜋-
stacking interaction with centroid of PWZ-029. (2) TYR 213 phenol
OH hydrogen bonding to imidazole nitrogen lone pair. (3) THR
210 OH and lone pair on methoxy of PWZ029. (4) 𝛼5 ribbon being
green. (5) 𝛾2 ribbon being yellow. (6) Hydrogen bonding being aqua
blue. (7) 𝜋-stacking being magenta.
able to reduce the behavioral sensitivity to psychostimulants
observed in MAM rats (Figures 20 and 21). This suggests
that novel 𝛼5-partial allostericmodulators should be effective
in alleviating dopamine-mediated psychosis. However, if
this drug can also restore rhythmicity within HPC-efferent
structure, it may also affect other aspects of this disease
state such as cognitive disabilities and negative symptoms.
This study, using the MAM-model to induce symptoms of
schizophrenia, shows that the use of 𝛼5-GABAAR targeting
compounds could be an effective treatment in schizophrenic
patients. The selective targeting solely of 𝛼5𝛽3𝛾2 subunits, as
opposed to unselective BZDs such as diazepam, could pro-
vide relief from the psychotic symptoms without producing
adverse effects such as sedation [27–38].
As reported by Gill, Grace et al. [36, 38, 47–61].
Often initial antipsychotic drug treatments (APD) for
schizophrenia are ineffective, requiring a brief washout
period prior to secondary treatment. The impact of with-
drawal from initial APD on the dopamine (DA) system
is unknown. Furthermore, an identical response to APD
therapy between normal and pathological systems should not
be assumed. In another study by Gill, Grace et al., 𝛼5 positive
allosteric modulator SH-053-2󸀠F-R-CH
3
(2) was used in the
MAM neurodevelopmental model of schizophrenia which
was used to study impact of withdrawal from repeated
haloperidol (HAL) on the dopamine system [36, 38, 47–61].
The following studies were designed to provide insight as
to why a new drug to treat schizophrenia may be effective
in Phase II clinical trials but fail in Phase III because of
the large number of patients required for the study. Many
of these patients in Phase III studies have altered neuronal
pathways in the CNS because of long-term treatment with
antipsychotics (sometimes 10–20 years) [36, 38, 47–61].
Importantly, spontaneous dopamine activity reduction
was observed in saline rats withdrawn from haloperidol with
an enhanced locomotor response to amphetamine, indicating
the development of dopamine supersensitivity. In addition,
PAM treatment, as well as ventral HPC inactivation, removed
the depolarization block of DA neurons in withdrawn HAL
treated SAL rats. In contrast, methylazoxymethanol rats
withdrawn from HAL displayed a reduction in spontaneous
dopamine activity and enhanced locomotor response that

















𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6Binding data
DM-I-81 (9)
DM-I-81 aligned in the included volume of the pharmacophore/receptor model for the 𝛼1𝛽3𝛾2 (blue) and 𝛼5𝛾3𝛽2 (red) subtypes
Figure 17: The 𝛼5 selective agonist DM-I-81 (9), bound within the 𝛼1 and 𝛼5 subtypes. Binding data shown as𝐾
𝑖
(nM).
was unresponsive to PAM treatment with SH-053-2󸀠F-R-CH
3
or ventral HPC inactivation [36, 38, 47–61].
Prior HAL treatment withdrawal can restrict the efficacy
of subsequent pharmacotherapy in the MAM model of
schizophrenia. This is an extremely important result indi-
cating that testing a new drug for schizophrenia in humans
treated for years with both typical and atypical antipsychotics
may result in a false negative with regard to treatment. Studies
that support this hypothesis follow here [36, 38, 47–61].
Novel therapeutics for the treatment of schizophrenia
that exhibit initial promise in preclinical trials often fail to
demonstrate sufficient efficacy in subsequent clinical trials. In
addition, relapse or noncompliance from initial treatments is
common, necessitating secondary antipsychotic intervention
[47, 48]. Studies have shown that between 49 and 74%
of schizophrenia patients discontinue the use of antipsy-
chotic drug (APD) treatments within 18 months due to
adverse side-effects [48, 49]. Current pharmacotherapies for
schizophrenia target the pathological increase in dopamine
system activity, as mentioned above. Common clinical prac-
tice for secondary antipsychotic application involves a brief
withdrawal period from the initial APD. Unfortunately, the
success of even secondary treatments is far from being opti-
mal with the rehospitalization of patients being a common
occurrence. The impact of repeated antipsychotic treatment
and subsequent withdrawal on the dopamine system has not
been adequately assessed [36, 38, 47–61].
As indicated above, schizophrenia is a complex chronic
psychiatric illness characterized by frequent relapses despite
ongoing treatment. The search for more effective pharma-
cotherapies for the treatment of schizophrenia continues
unabated. It is not uncommon for novel pharmaceuticals to
demonstrate promise in preclinical trials but fail to show
an adequate response in subsequent clinical trials. Indeed,
evaluating the benefits of one APD versus another is compli-
cated by clinical trials beset with high attrition rates and poor
efficacy in satisfactorily reducing rehospitalization [47, 49–
52].
Previous work from the Gill, Grace et al.’s laboratory
[36, 38, 47–61] with the MAM model of schizophrenia has
identified a potential novel therapeutic, a 𝛼5GABAAR PAM.
The dopamine system pathology in the MAMmodel is likely
the result of excessive output from the ventral HPC [36]. The
𝛼5GABAAR PAM was identified as a potential therapeutic
due to the relatively selective expression of 𝛼5GABAAR in
the ventral HPC and its potential for reducing HPC activity
[53–60]. When either administered systemically or directly
infused into the ventralHPC, the𝛼5GABAARPAM(SH-053-
2󸀠F-R-CH
3
) was effective in reducing the dopamine system
activation in MAM rats [38]. Anthony Grace, Gill et al.
showed 𝛼5GABAAR PAM treatment was also effective in
reducing the enhanced behavioral response to amphetamine
in MAM rats, as stated above. Data from the present study
sought to delineate whether the 𝛼5GABAAR PAM (SH-053-
2󸀠F-R-CH
3
) would remain effective in MAM rats withdrawn
from prior neuroleptic treatment, a common occurrence in
the patient population. In both SAL andMAM rats, there was
a reduction in the spontaneous activity of dopamine neurons
in the VTA after 7 days withdrawal from repeated HAL
treatment. However, MAM rats continued to exhibit a greater
activation of the dopamine system in comparison to SAL rats.
Treatment with the 𝛼5GABAAR PAMwas no longer effective
in reducing the activity of dopamine neurons in the VTA in
withdrawn HAL treated MAM rats. In contrast, 𝛼5GABAAR
PAM treatment in the withdrawn HAL treated SAL rats
instead increased the spontaneous activity of dopamine in the
VTA (Figures 22–25) [36, 38, 47–61].
Similar to the effects seen following 𝛼5GABAAR PAM
treatment, ventral HPC inactivation in withdrawn HAL
treated SAL rats restored normal dopamine system activity
by increasing the number of spontaneously active dopamine
neurons. The disparate effect of withdrawal from HAL on























































Figure 18: Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.; patterned bars) normalizes the aberrant increase in the number of spontane-
ously firing dopamine neurons (expressed as cells/track) inmethylazoxymethanol acetate- (MAM-) treated animals (a).There was no effect of
SH-053-2󸀠F-R-CH
3
treatment in control animals (open bars, (a)–(c)) or on firing rate and burst activity in MAM animals (dark bars; (b)-(c))
(∗𝑝 < 0.05, two-way ANOVA, Holm-Sidak post hoc;𝑁 = 5–7 rats/group) [27–38].
the dopamine system between SAL and MAM rats provides
a vital clue for the inconsistencies between preclinical trials
for novel therapeutics that utilize normal subjects and subse-
quent clinical trials in a patient population [36, 38, 47–61].
Thedata suggests underlying dopamine systempathology
alters the impact of withdrawal from prior repeated HAL in
the MAM model of schizophrenia. In addition, subsequent
novel APD treatment loses efficacy following withdrawal
from repeated HAL in MAM animals. This certainly has
relevance to Phase III clinical trials of new drugs to treat
schizophrenia [36, 38, 47–61].
7. GABAA 𝛼5 Positive Allosteric Modulators
Relax Airway Smooth Muscle
Emala, Gallos, et al. [66–75] have found that novel 𝛼5-
subtype selective GABAA positive allosteric modulators relax
airway smoothmuscle from rodents and humans.The clinical
need for new classes of bronchodilators for the treatment of
bronchoconstrictive diseases such as asthma remains a major
medical issue. Few novel therapeutics have been approved
for targeting airway smoothmuscle (ASM) relaxation or lung
inflammation in the last 40 years [66]. In fact, several asthma-
related deaths are attributed, in part, to long-acting 𝛽-
agonists (LABA) [67]. Adherence to inhaled corticosteroids,
the first line of treatment for airway inflammation in asthma,
is very poor [68, 69]. Therapies that break our dependence
on 𝛽-agonism for ASM relaxation would be a novel and
substantial advancement.
These ASM studies were undertaken due to a pressing
clinical need for novel bronchodilators in the treatment
of asthma and other bronchoconstrictive diseases such as
COPA. There are only three drug classes currently in clinical























































Figure 19: Hippocampal (HPC) infusion of SH-053-2󸀠F-R-CH
3
(1 𝜇M/side; patterned bars) normalizes the aberrant increase in the number
of spontaneously firing dopamine neurons (expressed as cells/track) in methylazoxymethanol acetate- (MAM-) treated animals (a). There
was no effect of SH-053-2󸀠F-R-CH
3
treatment in control animals (open bars, (a)–(c)) or on firing rate in MAM animals (dark bars; (b)).
Hippocampal (HPC) infusion of SH-053-2󸀠F-R-CH
3
significantly reduced the percentage of spikes occurring in bursts of dopamine (DA)
neurons in MAM and control animals (c) (∗𝑝 < 0.05, two-way ANOVA, Holm-Sidak post hoc;𝑁 = 7 rats/group) [27–38].
use as acute bronchodilators in the United States (methylxan-
thines, anticholinergics, and 𝛽-adrenoceptor agonists) [70].
Thus, a novel therapeutic approach that would employ
cellular signaling pathways distinct from those used by
these existing therapies involves modulating airway smooth
muscle (ASM) chloride conductance via GABAA receptors to
achieve relaxation of precontracted ASM [71, 72]. However,
widespread activation of all GABAA receptors may lead to
undesirable side effects (sedation, hypnosis, mucus forma-
tion, etc.). Thus, a strategy that selectively targets a subset
of GABAA channels, those containing 𝛼 subunits found to
be expressed in airway smooth muscle, may be a first step
in limiting side effects. Since human airway smooth muscle
contains only 𝛼4 or 𝛼5 subunits [72], ligands with selectiv-
ity for these subunits are an attractive therapeutic option.
Concern regarding nonselective GABAA receptor activation
is not limited to the airway or other peripheral tissues.
GABAA receptor ligands are classically known for their cen-
tral nervous system effects of anxiolysis, sedation, hypnosis,
amnesia, anticonvulsion, and muscle relaxant effects. Such
indiscriminate activation of GABAA receptors in the CNS is
exemplified by the side effects of classical benzodiazepines
(such as diazepam) which were the underpinning for the
motivation of a search for benzodiazepine (BZD) ligands that
discriminate among the 𝛼 subunits of GABAA receptors [73–
75].
A novel approach to identify novel benzodiazepine
derivatives to selectively target GABAA channels containing
specific 𝛼 subunits was developed by Cook et al. in the
1980s that employed a pharmacophore receptor model based
on the binding affinity of rigid ligands to BDZ/GABAA
receptor sites (as reviewed in 2007 [23]). From this series






































Figure 20: Extracellular recording traces illustrate the reduction in evoked responses in the ventral hippocampal (HPC) to entorhinal
cortex stimulation in bothMAM- and saline-treated animals (a, b). Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.) decreases the evoked
excitatory response (dashed lines) of ventral HPC neurons to entorhinal cortex stimulation in both MAM- and saline-treated animals (c)
(∗𝑝 < 0.05 for saline and +𝑝 < 0.05, two-way repeated measures ANOVA, Holm-Sidak post hoc) [27–38].
of receptor models for 𝛼
1–6𝛽3𝛾2 subtypes a robust model
for 𝛼5 subtype selective ligands emerged, the result of which
included the synthesis of a novel 𝛼5𝛽3𝛾2 partial agonist
modulator, SH-053-2󸀠F-R-CH
3
(2). The discovery of this and
related ligands selective for 𝛼5 BDZ/GABAA-ergic receptors
and the realization that only 𝛼4 and𝛼5 subunits are expressed
inGABAA channels on human airway smoothmuscle yielded
an ideal opportunity for targeting these 𝛼5-subunit contain-
ing GABAA channels for bronchorelaxation [66–75].
The GABAA𝛼5 subunit protein was first localized to the
ASM layer of human trachea while costaining for the smooth
muscle specific protein 𝛼 actin (Figure 26). The first panel of
Figure 26 shows GABAA 𝛼5 protein stained with fluorescent
green and blue fluorescent nuclear staining (DAPI). The
second panel is the same human tracheal smooth muscle
section simultaneously stained with a protein specific for
smooth muscle, 𝛼 actin, and the third panel is a merge of
the first two panels showing costaining of smooth muscle
with GABAA 𝛼5 and 𝛼 actin proteins. The fourth panel is
a control omitting primary antibodies but including nuclear
DAPI staining [66–75].
After demonstrating the protein expression of GABAA
receptors containing the 𝛼5 subunit, functional studies of
isolated airway smooth muscle were performed in tracheal
airway smooth muscle from two species. Human airway
smooth muscle suspended in an organ bath was precon-
tracted with a concentration of acetylcholine that was the
EC
50
concentration of acetylcholine for each individual
airway smooth muscle preparation. The induced contraction
was then relaxed with a 𝛽-agonist (isoproterenol) in the




(2). Figure 27(a) shows that the amount of relaxation






















































Figure 21: Treatment with SH-053-2󸀠F-R-CH
3
(10mg/kg, i.p.) reduced the aberrant increased locomotor response to D-amphetamine
(0.5mg/kg i.p.) observed in MAM rats (a). MAM animals demonstrated a significantly larger peak locomotor response than both saline-
treated animals and MAM animals pretreated with the alpha-5 PAM (b) (there was a significant difference between MAM-vehicle and all
other groups, ∗𝑝 < 0.05, two-way repeated measures ANOVA, Holm-Sidak post hoc) [27–38].
induced by 10 nM isoproterenol was significantly increased if
50𝜇M SH-053-2󸀠F-R-CH
3
(2) was also present in the buffer
superfusing the airway smoothmuscle strip. Studieswere also
performed in airway smooth muscle from another species,
guinea pig, that measured direct relaxation of a different
contractile agonist, substance P. As shown in Figure 27(b),
the amount of remaining contractile force 30 minutes after
a substance P-induced contraction was significantly reduced




Following these studies in intact airway smooth muscle,
cell based studies were initiated in cultured human airway
smooth muscle cells to directly measure plasma membrane
chloride currents and the effects of these currents on intracel-
lular calcium concentrations. SH-053-2󸀠F-R-CH
3
(2) induced
a Cl− current in vitro using conventional whole cell patch
clamp techniques [66–75]. These electrophysiology studies
were then followed by studies to determine the effect of these
plasma membrane chloride currents on intracellular calcium
concentrations following treatment of human airway smooth
muscle cells with a ligand whose receptor couples through a
Gq protein pathway, a classic signaling pathway thatmediates
airway smooth muscle contraction.
SH-053-2󸀠F-R-CH
3
(2) attenuated an increase in intracel-
lular calcium concentrations induced by a classic Gq-coupled
ligand, bradykinin (Figure 28(a)) [66–75]. The attenuation
by SH-053-2󸀠F-R-CH
3
(2) was significantly blocked by the
GABAA antagonist gabazine (Figure 28(b)) indicating that
SH-053-2󸀠F-R-CH
3
(2) wasmodulatingGABAA receptors for
these effects on cellular calcium [66–75].
The major findings of these studies are that human
airway smooth muscle expresses 𝛼5 subunit containing
GABAA receptors that can be pharmacologically targeted
by a selective agonist. The GABAA 𝛼5 subunit selective
ligand SH-053-2󸀠F-R-CH
3
(2) relaxed intact guinea pig
airway smooth muscle contracted with substance P and
augmented 𝛽-agonist-mediated relaxation of intact human
airway smooth muscle. The mechanism for these effects
was likely mediated by plasma membrane chloride currents
that contributed to an attenuation of contractile-mediated
increases in intracellular calcium, a critical event in the initi-
ation and maintenance of airway smooth muscle contraction
[66–75].




to Other Bz/GABAergic Subtypes
The findings in both the MAM-model of schizophrenia and
the relaxation of airway smooth muscle have led to the study
of SH-053-2󸀠F-R-CH
3
and related compounds bound within
the𝛼5-GABAA/BzR (Figure 29).The SH-053-R-CH3 (15) and
SH-053-S-CH
3
(16) isomers have been previously described





have been tested for binding affinity and
show selectivity for the 𝛼5-subunit (Table 3).
From examination of Figure 30 and Tables 3 and 4, it is
clear the (R)-isomers bound to the 𝛼5 subtype while the (S)-
isomers were selective for 𝛼2/𝛼3/𝛼5 subtypes.
From this data, these compounds were then used in
examining the 𝛼5-binding pocket, most specifically the
fluoroseries. In regard to molecular modeling, depicted in






enantiomers in the 𝛼5 subtype as well as the 𝛼2 subtype. It





































































































































































































Figure 22: Repeated haloperidol treatment caused a reduction in the number of spontaneously active dopamine neurons in both SAL and
MAM rats injected with vehicle compared to untreated control animals. Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.) reversed the
haloperidol-induced reduction in cells/track in SAL, but not MAM, rats (a). Repeated haloperidol treatment had no effect on the firing rate
of dopamine neurons recorded in SAL or MAM rats treated with vehicle. However, SH-053-2󸀠F-R-CH
3
caused an increase in firing rate of
dopamine neurons in repeatedly haloperidol-treated SAL rats (b). Repeated haloperidol treatment, as well as SH-053-2󸀠F-R-CH
3
injection,
had no impact on the percentage of spikes occurring in bursts for dopamine neurons recorded in SAL and MAM rats (c) [36, 38, 47–61].
∗
𝑝 < 0.05.
is clear a new pocket (𝐿
4
) has been located in the 𝛼5 subtype
permitting 2 as well as 17 to bind to the 𝛼5 subtype. Exami-
nation of both ligands in the 𝛼2 subtype clearly illustrates the
analogous region in the 𝛼2 subtype is not present and thus
does not accommodate 2 for the pendant phenyl which lies
outside the included volume in the space allocated for the
receptor protein itself [23].
9. BzR GABA(A) Subtypes
In terms of potency, examination of the values in Table 4 [87],
it is clear the R-isomer (2) shows more selectivity towards the
𝛼5-subunit, while the S-isomer (17) is potent at the 𝛼2/3/5
subunits. It is important, as postulated earlier [23], that the
major difference in GABA(A)/Bz receptors subtypes stems















































































































































































































Figure 23: Repeated haloperidol treatment caused a reduction in the number of spontaneously active dopamine neurons in both SAL and
MAMratsmicroinfusedwith vehicle in the ventral HPC compared to untreated control animals. Infusion of TTX in the ventral HPC reversed
the haloperidol-induced reduction in cells/track in SAL, but not MAM, rats (a). Repeated haloperidol treatment had no effect on the firing
rate of dopamine neurons recorded in SAL orMAM rats infused with vehicle or TTX in the ventral HPC (b). Repeated haloperidol treatment
had no effect on the percentage of spikes occurring in bursts for dopamine neurons recorded in SAL or MAM rats infused with vehicle or
TTX in the ventral HPC (c) [36, 38, 47–61]. ∗𝑝 < 0.05.









, and 𝐿Di in the pharmacophore/receptor model
and indicates even better functional selectivity is possible
with asymmetric BzR ligands.
The synthetic switching of chirality at the C-4 position
of imidazobenzodiazepines to induce subtype selectivity was
successful. Moreover, increase of the potency of imidazoben-
zodiazepines can be achieved by substitution of the 2󸀠-
position hydrogen atomwith an electron rich atom (fluorine)
on the pendant phenyl ring in agreement with Haefely et al.
[88], Fryer [89, 90], and our ownwork [22, 91].The biological
data on the two enantiomeric pairs of benzodiazepine ligands


















































Figure 24: Administration of apomorphine (80mg/kg i.v.)
increased the number of spontaneously active dopamine neurons in
SAL rats withdrawn from repeated HAL, while having no effect on
the number of active dopamine neurons in MAM rats withdrawn
from repeated HAL [36, 38, 47–61]. ∗𝑝 < 0.05.
Table 3: Binding affinity at 𝛼𝑥𝛽2𝛾2 GABAA receptor subtypes
(values are reported in nM).
Compounda 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-053-R-CH
3
, (15) 2026 2377 1183 >5000 949.1 >5000
SH-053-S-CH
3
, (16) 1666 1263 1249 >5000 206.4 >5000
SH-053-2󸀠F-R-CH
3
, (2) 759.1 948.2 768.8 >5000 95.17 >5000
SH-053-2󸀠F-S-CH
3
, (17) 350 141 1237 >5000 19.2 >5000
aData shown here are themeans of two determinations which differed by less
than 10%.
Table 4: Oocyte electrophysiological data of benzodiazepinesa [87].
Compound 𝛼1 𝛼2 𝛼3 𝛼5
SH-053-2󸀠F-R-CH
3
(2) 111/154 124/185 125/220 183/387
SH-053-2󸀠F-S-CH
3
(17) 116/164 170/348 138/301 218/389
aEfficacy at 𝛼𝑥𝛽3𝛾2 GABAA receptor subtypes as % of control current at
100 nM and 1 𝜇M concentrations. Data presented as percent over baseline
(100) at concentrations of 100 nM/1 𝜇M.
confirm the ataxic activity of BZ site agonists is mediated by
𝛼1𝛽2/3𝛾2 subtypes, as reported in [23, 91–93].The antianxiety
activity in primates of the S isomers was preserved with
no sedation. In only one study in rodents was any sedation
observed; the confounding sedation was observed in both the
S isomer (functionally selective for 𝛼2, 𝛼3, and 𝛼5 receptor
subtypes) and R isomer (essentially selective for 𝛼5 subtype)
and may involve at least, in part, agonist activity at 𝛼5 BzR
subtypes. There are some 𝛼5 BzR located in the spinal cord






this is possibly some type of stereotypical behavior. Hence in
agreement with many laboratories including our own [23, 92,
93] the best potential nonsedative, nonamnesic, antianxiety
agents stem from ligands with agonist efficacy at 𝛼2 subtypes
essentially silent at 𝛼1 and 𝛼5 subtypes (to avoid sedation)
[91]. It must be pointed out again; however, in primates
Fischer et al. [87] observed a potent anxiolytic effect with no
sedation with the 2󸀠F-S-CH
3
(17) isomer, while the 2󸀠F-R-
CH
3
(2) isomer exhibited only a very weak anxiolytic effect.
Numerous groups have done modeling and SAR studies
on different classes of compounds which have resulted in
a few different pharmacophore models based on the ben-
zodiazepine binding site (BS) of the GABAA receptor [94].
These models are employed to gain insight in the interactions
between the BS and the ligand. These have been put forth
by Loew [7, 95, 96], Crippen [97, 98], Codding [76, 77, 99–
101], Fryer [89, 90, 94], Gilli and Borea [102–105], Tebib et al.
[106], and Gardner [107], as well as from Professors Sieghart,
Cromer, and our own laboratory [21, 39, 40, 76, 78–82, 108–
118].
The Milwaukee-based pharmacophore/receptor model
is a comprehensive building of the BzR using radioligand
binding data and receptor mapping techniques based on 12
classes of compounds [20, 23, 39, 40, 42, 111, 119–122]. This
model (Figure 31) [79] has brought together previous models
which have used data from the activity of antagonists, positive
allosteric modulators, and negative allosteric modulators and
included the newmodels for the “diazepam-insensitive” (DI)





















represent negative areas of
steric repulsion. As previously reported, the synthesis of both
partial agonists and partial inverse agonists has been achieved
by using parts of this model [99, 100, 104, 105, 119, 124–127].
The cloning, expression, and anatomical localization
of multiple GABA(A) subunits have facilitated both the
identification and design of subtype selective ligands. With
the availability of binding data from different recombinant
receptor subtypes, affinities of ligands from many different
structural classes of compounds have been evaluated.
Illustrated in Figure 31 is the [3,4-c]quinolin-3-one CGS-
9896 (18) (dotted line), a diazadiindole (19) (thin line), and
diazepam (20) (thick line) fitted initially to the inclusive




(H102) represent hydrogen bond donor sites on the receptor
protein complex while𝐴
2
(T142) represents a hydrogen bond


















Based on SAR data obtained for these ligands at 6 recom-
binant BzR subtypes [128–132], an effort has been undertaken
to establish different pharmacophore/receptor models for
BzR subtypes.The alignment of the twelve different structural
classes of benzodiazepine receptor ligands was earlier based
on the least squares fitting of at least three points. The









) employed in the alignment are outlined in Figure 32.
































































































































(c) Postamphetamine average peak distance travelled
Figure 25: Repeated haloperidol treatment causes an enhancement in the locomotor response to D-amphetamine (0.5mg/kg, i.p.) in
SAL animals that is reduced by pretreatment with SH-053-2󸀠F-R-CH
3
(10mg/kg, i.p.) (a). MAM rats treated repeatedly with haloperidol
exhibit a locomotor response following D-amphetamine similar to untreated MAM rats. However, repeated haloperidol treatment blocks
the effect of SH-053-2󸀠F-R-CH
3
pretreatment in decreasing the locomotor response in MAM rats (b). Untreated MAM rats demonstrated a
significantly larger peak locomotor response than untreated SAL rats. In addition, SH-053-2󸀠F-R-CH
3
pretreatment significantly reduced
the peak locomotor response in untreated MAM rats, while having no effect in repeatedly haloperidol-treated MAM rats. In contrast,
repeated haloperidol treatment enhanced the peak locomotor response to amphetamine in SAL rats that was reduced by SH-053-2󸀠F-R-CH
3
pretreatment (c) [36, 38, 47–61]. ∗𝑝 < 0.05.
Herein are described the results from ligand-mapping exper-
iments at recombinant BzR subtypes of 1,4-benzodiazepines,
imidazobenzodiazepines, 𝛽-carbolines, diindoles, pyrazolo-
quinolinones, and others [126]. Some of the differences and
similarities among these subtypes can be gleaned from this
study and serve as a guide for future drug design.
10. 𝛼1 Updates
10.1. Beta-Carbolines. A series of 3,6-disubstituted 𝛽-carbo-
lines was prepared and evaluated for their in vitro affinity
at 𝛼x𝛽3𝛾2 GABA(A)/BzRr subtypes by radioligand binding
assays in search of 𝛼1𝛽3𝛾2 subtype selective compounds
(Figure 33). A potential therapeutic application of such antag-
onist analogs is to treat alcohol abuse [133, 134]. Analogues
of 𝛽CCt (21) were synthesized via a carbonyldiimidazole-
mediated method by Yin et al. [85] and the related 6-
substituted 𝛽-carboline-3-carboxylates including WYS8 (27)
were synthesized from6-iodo𝛽CCt (29). Bivalent ligands (42
and 43) were also synthesized to increase the scope of the
structure-activity relationships (SAR) to larger ligands. An

















Figure 26: Protein expression of the GABAA 𝛼5 subunit in intact human trachea-bronchial airway smooth muscle. Representative
images of human tracheal airway smooth muscle sections using confocal microscopy are depicted following single, double, and triple
immunofluorescence labeling.The antibodies employed were directed against the GABAA 𝛼5 subunit (green), 𝛼-smoothmuscle actin (SMA;
red), and/or the nucleus via DAPI counterstain (blue). Panels illustrate the following staining parameters from left to right: (1st) costaining
of DAPI and GABAA 𝛼5 subunit; (2nd) 𝛼-SMA staining alone; (3rd) triple-staining of GABAA 𝛼5, 𝛼-SMA, and DAPI; (4th) DAPI nucleus










































































(2) mediated activation of 𝛼5 subunit containing GABAA channels induces relaxation of precontracted
airway smooth muscle. (a) SH-053-2󸀠F-R-CH
3
(2) (SH-053) potentiates 𝛽-agonist-mediated relaxation of human airway smooth muscle.
Cotreatment of human airway smooth muscle strips with SH-053-2󸀠F-R-CH
3
(2) (50𝜇M) significantly enhances isoproterenol (10 nM)
mediated relaxation of an acetylcholine EC
50
contraction compared to isoproterenol alone (𝑁 = 8/group, $$ = 𝑝 < 0.01). Modified from
[66–75]. (b) SH-053-2󸀠F-R-CH
3
(2) activation of 𝛼5 containing GABAA receptors induces direct relaxation of substance P-induced airway
smoothmuscle contraction. Compiled results demonstrating enhanced spontaneous relaxation (expressed as% remaining force at 30minutes
following a 1 𝜇M substance P mediated contraction) following treatment with SH-053-2󸀠F-R-CH
3
(2) compared to treatment with vehicle
control (𝑛 = 4-5/group, $$ = 𝑝 < 0.01) [66–75].
initial SARon the first analogs demonstrated that compounds
with larger side-groups at C6 were well tolerated as they
projected into the𝐿Di domain (see 42 and 43) [85].Moreover,
substituents located at C3 exhibited a conserved stereo inter-
action in lipophilic pocket 𝐿
1
, while N2 likely participated in
hydrogen bonding with 𝐻
1
. Three novel 𝛽-carboline ligands
(21, 23, and 27) permitted a comparison of the pharmaco-
logical properties with a range of classical benzodiazepine
receptor antagonists (flumazenil, ZK93426) from several
structural groups and indicated these𝛽-carbolineswere “near
GABA neutral antagonists.” Based on the SAR, the most
potent (in vitro) 𝛼1 selective ligand was the 6-substituted
acetylenyl 𝛽CCt (WYS8, 27). In a previous study both 21
and 23 were able to reduce the rate at which rats self-
administrated alcohol in alcohol preferring and HAD rats
but had little or no effect on sucrose self-administration [85].


























Pretreatment: Vehicle SH-053 Gabazine Gabazine/
SH-053

















(2) mediated activation of 𝛼5 containing GABAA receptors attenuates bradykinin-induced elevations in cytos-
olic Ca2+ in human airway smoothmuscle cells. (a) Representative Fluo-4 Ca2+ fluorescence (RFU) tracing illustrating pretreatment with SH-
053-2󸀠F-R-CH
3
(2) (SH-053) (10 𝜇M) reduces cytosolic Ca2+ response to bradykinin (1 𝜇M).This effect is reversed in the presence of gabazine




GABAA 𝛼5 receptors on human airway smooth muscle cells attenuates bradykinin-induced elevations in intracellular Ca
2+ compared to
levels achieved following pretreatment with vehicle control ($$ = 𝑝 < 0.01). While gabazine-mediated blockade of GABAA channels does
not significantly affect bradykinin-induced intracellular calcium increase compared to vehicle control, gabazine treatment did reverse SH-
053-2󸀠F-R-CH
3
(2) ability to attenuate bradykinin-induced elevations in intracellular calcium thereby illustrating a GABAA channel specific






















SH-053-S-CH3, 16SH-053-R-CH3, 15 SH-053-2󳰀F-S-CH3, 17SH-053-2󳰀F-R-CH3, 2
Figure 29: Structures of enantiomers with 2󸀠H (15, 16) and 2󸀠F (2, 17).
3-PBC (23) was also active in baboons [134]. This data has
been used in updating the pharmacophore model in the 𝛼1-
subtype.
11. The Updated Included Volume Models
Illustrated in Figure 34 is the included volume of the updated
pharmacophore receptor model of the 𝛼1𝛽3𝛾2 subtype of
Clayton [22]. The current model for the 𝛼1𝛽3𝛾2 subtype
has several new features. The cyclopropyl group of CD-214
extended 2 A˚ past the 𝐴
2
descriptor slightly increasing its
volume. The trimethylsilyl group of QH-II-82 and WYS7
illustrates how well bulky groups are tolerated near the
entrance of the binding pocket. Despite not being as potent,
dimers of beta carbolines, WYS2 and WYS6, bound to 𝛼1
subtypes at 30 nM and 120 nM, respectively. Their ability
to bind, albeit weakly, supports the location of the binding
site entrance from the extracellular domain. The included
volume of the 𝛼1𝛽3𝛾2 subtype was previously 1085.7 cubic
angstroms. The volume has now been measured as 1219.2
cubic angstroms. Volume measurements should be used
carefully as the binding site is not enclosed and the theo-
retical opening near 𝐿DI is not clearly demarcated. Dimers
were excluded from the included volume exercise because
although they bound to the receptor, they represented com-
poundswhichwere felt to extend outside the receptor binding
pocket when docked to the protein. Where appropriate,
22 International Journal of Medicinal Chemistry
included volume of the alpha 2 subtype
included volume of the alpha 2 subtype
included volume of the alpha 5 subtype
included volume of the alpha 5 subtype fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 2
fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 17
fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 17
The left image of figure rotated 90∘ . It can be clearly seen
that the conformation of 2 is such that the pendant 6-phenyl sticks
outside the included volume
L4
SH-053-2󳰀F-R-CH3 2 fits the pharmacophore in the
SH-053-2󳰀F-S-CH3 17 fits the pharmacophore in the
SH-053-2󳰀F-S-CH3 17 fits the pharmacophore in the
SH-053-2󳰀F-R-CH3 2 does not fit the pharmacophore in the




2 enantiomers in the 𝛼5 and 𝛾2
pharmacophore/receptor models. This figure was modified and reproduced from that reported by Clayton et al. in [22, 23].


























Figure 31:The two-dimensional representation of the Milwaukee-based unified pharmacophore with 3 amino acids in the binding site based
on the rigid ligand template [23, 39, 42, 76–80].This figure has beenmodified from that reported for PAMs, NAMs, and antagonists in [22, 23].














A2 is on the plane of
H2 is 0.1Å below the plane
H1 is on the plane of the





a = 6.735Å; b = 9.980Å; c = 5.860Å
d = 5.734Å; e = 5.218Å; f = Å7.317
Figure 32:The schematic representation of the descriptors for the initial inclusive BzR pharmacophore based on the rigid ligands (diindoles)
[79, 81–84]. This figure has been modified from that reported in [79].
their monomers were included in the included volume
analysis. Ligands considered for the included volume in
Table 5 exhibited potent binding at 𝛼1 subtypes (𝐾
𝑖
≤ 20 nM)
but were not necessarily subtype selective. The binding
data for ligands at 𝛼
2–6-subtypes follow (Tables 6–10; struc-
tures located in Clayton [22] and Supporting Information,
Appendix III in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/430248).
12. The 𝛼1𝛽3𝛾2 Receptor Subtype
The focus of this research was aimed at diazepam sensitive
receptors; additional features to the 𝛼4𝛽3𝛾2 and 𝛼6𝛽3𝛾2
receptors were not identified (see Table 5, Figures 34 and 35).
Themajor new feature identified for the 𝛼5𝛽3𝛾2 receptor was
a new 𝐿
4






enantionmers as well as the 2󸀠F analogs [74, 135, 136].






















































































1.2 4.9 5.7 ND 26.8 2,700
6.8 30 36 2000 108 1000
17 59 88 200 1444 >3000
4.4 4.5 5.58 2000 47 2000
0.972 111 102 2000 1473 1980
4.5 44.6 42.7 2000 124 2000
14.4 44.9 123 >4000 65.3 >4000
12 39 47 2000 122 3000
4.8 31 34 1000 286 1000
78 301 131 3000 681 3000
2.4 13 27.5 NA 163 5000
26 143 117 3000 127 2000
37 166 314 NA 2861 5000
9.2 13 72 2000 449 2000
3.63 2.02 44.3 NA 76.5 5000
25 137 125 2000 299 2000
3.7 27 40 NA 254 >2500
2.78 8.93 24.5 1000 7.49 1000
1.62 4.54 14.7 1000 4.61 1000
30 124 100 >300 >300 >4000
120 1059 3942 5000 5000 5000
5.3 52.3 68.8 1000 591
aAffinity of compounds at GABA(A)/BzR recombinant subtypes was measured by competition for [3H]ﬂunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes expressing human
receptors of composition 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [85]. Data represent the average of at least three determinations with a SEM of ±5%.
CO2Et
Figure 33: aAffinities (𝐾
𝑖
= nM) of 3,6-disubstituted 𝛽-carbolines at 𝛼𝑥𝛽3𝛾2 (𝑥 = 1–3, 5, 6) receptor subtypes [85].The structures versus code
numbers of all ligands in the tables of this review can be found in the Ph.D. thesis of Terry Clayton (Ph.D. thesis, University of Wisconsin-
Milwaukee, Milwaukee, WI, December, 2011) [22] and in the Supporting Information.
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Table 5: These ligands bound with potent affinity for 𝛼1; ligands bound with 𝐾
𝑖
values <20 nM at this subtype.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
WY-TSC-4 (WYS8) 0.007 0.99 1.63 51.04
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 69.32
QH-II-090 (CGS-8216) 0.05 0.08 0.12 0.25 17
XLI-286 0.051 0.064 0.118 0.684
QH-II-077 0.06 0.08 0.05 0.12 4
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
JYI-57 0.076 0.076 0.131 ND 0.036 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
CGS8216 0.13 ND ND ND ND 46
SPH-121 0.14 1.19 1.72 ND 4 479
QH-II-075 0.18 0.21 0.25 ND 1.3 40
PZII-028 0.2 ND 0.2 ND 0.32 1.9
CGS9895 0.21 ND ND ND ND 9.3
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
XHE-III-24 0.25 ND 8 222 10 328
JYI-42 0.257 0.146 0.278 ND 0.256 ND
CGS9896 0.28 ND ND ND ND 181
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
PZII-029 0.34 ND 0.79 ND 0.52 10
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
FG8205 0.4 2.08 1.16 ND 1.54 227
YT-5 0.421 0.6034 36.06 ND 1.695 ND
6-PBC 0.49 1.21 2.2 ND 2.39 1343
QH-146 0.49 ND 0.76 ND 7.7 10000
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
BCCt 0.72 15 18.9 ND 110.8 5000
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
alprazolam 0.8 0.59 1.43 ND 1.54 10000
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
WYS10 C14H9F3N2O2 0.88 36 25.6 ND 548.7 15.3
WY-B-15 0.92 0.83 0.58 2080 4.42 646
WY-A-99-2 (WYS8) 0.972 111 102 2000 208 1980
XHE-III-06a 1 2 1 5 1.8 37
Xli366 C22H21N3O2 1 ND ND ND ND ND
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
BCCE 1.2 4.9 5.7 ND 26.8 2700
XHE-III-04 1.2 2 1.1 219 0.4 500
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
DM-239 1.5 ND 0.53 ND 0.14 6.89
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
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Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
TG-4-39 1.6 34 24 5.6 1.4 23
TG-II-82 1.6 2.9 2.8 ND 1 1000
CM-A87 1.62 4.54 14.73 1000 4.61 1000
QH-II-082 1.7 1.8 1.6 ND 6.1 100
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
LJD-III-15E 1.93 14 19 ND 70.8 1000
SPH-38 2 5.4 10.8 ND 18.5 3000
XHE-I-093 2 7.1 8.9 1107 20 1162
MSA-IV-35 2.1 16 21 ND 995 3000
JYI-19 (C23H23N3O3S) 2.176 205 ND ND 34 12.7
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
YCT-5 2.2 11.46 16.3 ND 200 10000
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
WYS13 C20H18N2O3 2.442 13 27.5 ND 163 5000
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
XHE-III-14 2.6 10 13 2 7
WYS9 C16H15IN2O2 2.72 22.2 23.1 ND 562 122
JYI-47 2.759 2.282 0.511 ND 0.427 ND
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
JYI-54 (C24H15N3O3F4) 2.89 172 6.7 ND 57 1890
MMB-II-74 3 24.5 41.7 500 125.7 1000
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
QH-II-080b 3 3.7 4.7 ND 24 1000
YCT-7A 3 23.8 30.5 ND 240 10000
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
XHE-II-017 3.3 10 7 258 17 294
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
MLT-II-18 3.4 11.7 11 ND 225 10000
TJH-V-88 3.41 30 ND 140.9 10000
XLI-2TC 3.442 1.673 44.08 ND 1.121
WYS15 C22H20N2O2 3.63 2.02 44.3 ND 76.5 5000
CM-A57 3.7 27 40 ND 254 1000
XHE-II-006b 3.7 15 12 1897 144 1000
JYI-60 3.73 1.635 4.3 ND 1.7 5000
RY-008 3.75 7.2 4.14 ND 1.11 44.3
MLT-II-18 3.9 12.2 24.4 ND 210 10000
OMB-18 3.9 1.2 3.4 1733 0.8 5
WY-B-09-1 3.99 8 32 1000 461 2000
SHU-1-19 4 12 7 48 14 84
ZK 93423 4.1 4.2 6 ND 4.5 1000
WY-B-23-2 (WYS11) 4.2 37.7 39 2000 176 69.4
WY-B-23-2 (WYS11) 4.2 37.7 73 ND 176 69.4
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
WY-B-26-2 4.45 44.57 42.66 2000 124 2000
XHE-II-006a 4.7 4.4 20 1876 89 3531
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Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-B01 4.8 31 34 1000 286 1000
PWZ-085 4.86 13 8.5 ND 0.55 40
MLT-II-16 5.05 10.41 18.4 ND 260 10000
3 PBC 5.3 52.3 68.8 ND 591 1000
MA-3-PROPOXYL 5.3 52.3 68.8 ND 591 1000
TJH-IV-43 5.42 30.19 48.9 ND 475 10000
DMCM 5.69 8.29 4 ND 1.04 134
DM-139 5.8 ND 169 ND 9.25 325
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
XLi343 C20H19ClN2OSi 6.375 17.71 ND ND 150.5 ND
3 EBC 6.43 25.1 28.2 ND 826 1000
DM-146 6.44 ND 148 ND 4.23 247
DM-215 6.74 ND 7.42 ND 0.293 8.28
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
WY-B-14 (WYS7) 6.84 30 36 2000 108 1000
YT-II 6.932 0.8712 3.518 ND 5.119 ND
SVO-8-67 7 41 26 15 2.3 191
MLT-II-34 7.04 15.95 22.3 ND 158 1000
SPH-195 7.2 168.5 283.5 ND 271 10000
XHE-I-065 7.2 17 18 500 57 500
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
XHE-I-038 7.3 5 34 ND 132 1000
XHE-III-13 7.3 ND 7.1 880 1.6 311
WY-B-25 7.6 40 66 2000 263 2000
CM-A49 (R) 7.7 32.5 43 ND 69 1000
SVO-8-14 8 25 8 6.9 0.9 14
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
XHE-II-002 8.3 18 13 3.9 1.5 11
WY-B-14 (WYS7) 8.5 165 245 ND 1786 5000
XHE-II-011 9 60 39 3233 90 1000
WY-B-27-2 9.19 111 72 2000 449 2000
QH-II-063 9.4 9.3 31 ND 7.7 3000
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
RY-I-31 10 45 19 ND 6 1000
WY-B-23-1 10 33 43 1000 189 2000
RY-098 10.1 22.2 16.5 ND 1.68 100
Hz148 C18H15N3 10.98 5000 ND ND 256 5000
SVO-8-20 11 40 28 19 8.6 138
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
PWZ-096 11.1 36 16.9 ND 1.07 51.5
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
CM-A77 11.51 51.9 105.16 1000 42.62 1000
WY-B-20 12 39 47 2000 122 3000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
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Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
ZG-213 12.8 49.8 30.2 ND 3.5 22.5
EDC-I-071 12.9 83.1 ND ND 314 5000
MMB-III-14 13 13 6.9 333 1.1 333
DM-173 13.1 ND 38.1 ND 0.78 118
XLI-348 13.56 11.17 1.578 ND 82.05 ND
EDC-I-093 13.6 423 ND ND 2912 5000
diazepam 14 20 15 ND 11 ND
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
WYSC2 C15H11F3N2O2 14.14 113 170 ND 518 61.2
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
CM-A100 14.49 44.91 123.8 1000 65.31 1000
RY-033 14.8 56 25.3 ND 1.72 22.9
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
YT-6 15.31 87.8 60.49 ND 1.039 ND
EDC-II-044 15.4 ND 293 ND 323 1000
CM-A58 16 120 184 ND 1000 1012
QH-II-067a 16 31 52 ND 199 3000
CD-214 16.4 48.2 42.5 ND 9.8 168
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
CM-A50 (S) 17 59 88 ND 144 1000
RY-061 17 13 6.7 ND 0.3 31
ZG-224 17.1 33.7 50 ND 2.5 30.7
ZG-63A 17.3 21.6 29.1 ND 0.65 4
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
CM-A64 18 60 116 ND 216 1000
RY-071 19 56 91 ND 7.2 266
WZ-113 19.2 13.2 13.4 ND 11.5 300
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
CM-E09b 20 22 19 55 0.45 69
MMB-II-90 20 24 5.7 9 0.25 36
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [139]. Data represent the average of at least
three determinations with a SEM of ±5%. The structures of these ligands are in the Ph.D. thesis of Clayton (2011) [22] and Supporting Information.
13. The 𝛼2𝛽3𝛾2 Receptor Subtype
See Table 6 and Figures 36 and 37.
14. The 𝛼3𝛽3𝛾2 Receptor Subtype
See Table 7 and Figures 38 and 39.
15. The 𝛼4𝛽3𝛾2 Receptor Subtype
See Table 8 and Figures 40 and 41.
16. The 𝛼5𝛽3𝛾2 Receptor Subtype
The multiple volume contours displayed in Figures 34–47
were created using the mvolume function (multiple volume
contour function) in Sybyl and compounds with binding
affinity at the receptor less than or equal to 20 nM. To create
the overlays, first, the display (dsp) and contour (cnt) files
were created for the 𝛼5𝛽3𝛾2 receptor subtype and the 𝛼1𝛽3𝛾2
receptor subtype by overlaying the compounds for each of
these receptors (see Table 9 and Figures 42–45). Using the
mvolume function, a logical expression was entered to create
the surfaces making up the union as well as the included
volume for each receptor subtype itself. It is clear from the
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Table 6: Ligands with potent affinity for 𝛼2; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 ND 69.32 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
XLI-286 0.051 0.064 0.118 ND 0.684 ND
JYI-57 0.076 0.076 0.131 ND 0.036 ND
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
QH-II-077 0.06 0.08 0.05 ND 0.12 4
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
JYI-42 0.257 0.146 0.278 ND 0.256 ND
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
QH-II-075 0.18 0.21 0.25 ND 1.3 40
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
alprazolam 0.8 0.59 1.43 ND 1.54 10000
YT-5 0.421 0.6034 36.06 ND 1.695 ND
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
WY-B-15 0.92 0.83 0.58 2080 4.42 646
YT-II 6.932 0.8712 3.518 ND 5.119
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
WY-TSC-4 (WYS8) 0.007 0.99 1.63 ND 51.04 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
SPH-121 0.14 1.19 1.72 ND 4 479
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
OMB-18 3.9 1.2 3.4 1733 0.8 5
6-PBC 0.49 1.21 2.2 ND 2.39 1343
YT-III-271 32.54 1.26 2.35 ND 103 ND
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
DM-II-72 (C15H10N20BrCl) 5000 1.37 ND ND 2.02 5000
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
XLI-2TC 3.442 1.673 44.08 ND 1.121 ND
QH-II-082 1.7 1.8 1.6 ND 6.1 100
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
XHE-III-06a 1 2 1 5 1.8 37
XHE-III-04 1.2 2 1.1 219 0.4 500
WYS15 C22H20N2O2 3.63 2.02 44.3 ND 76.5 5000
FG8205 0.4 2.08 1.16 ND 1.54 227
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
JYI-47 2.759 2.282 0.511 ND 0.427 ND
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
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Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
SPH-165 0.63 2.79 4.85 ND 10.4 1150
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
TG-II-82 1.6 2.9 2.8 ND 1 1000
QH-II-080b 3 3.7 4.7 ND 24 1000
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
PS-1-34B C20H17N4BrO ND 4.198 3.928 ND ND ND
ZK 93423 4.1 4.2 6 ND 4.5 1000
XHE-II-006a 4.7 4.4 20 1876 89 3531
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
CM-A87 1.62 4.54 14.73 1000 4.61 1000
OMB-19 22 4.6 20 3333 3.5 40
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
BCCE 1.2 4.9 5.7 ND 26.8 2700
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
XHE-I-038 7.3 5 34 ND 132 1000
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
SPH-38 2 5.4 10.8 ND 18.5 3000
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
XHE-I-093 2 7.1 8.9 1107 20 1162
RY-008 3.75 7.2 4.14 ND 1.11 44.3
DMH-D-053 (C43H30N6O4) 236 7.4 272 5000 194.2 5000
WY-B-09-1 3.99 8 32 1000 461 2000
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
DMCM 5.69 8.29 4 ND 1.04 134
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
QH-II-063 9.4 9.3 31 ND 7.7 3000
9.4 9.3 31 ND 7.7 3000
XHE-II-017 3.3 10 7 258 17 294
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
MLT-II-16 5.05 10.41 18.4 ND 260 10000
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
XLI-348 13.56 11.17 1.578 ND 82.05 ND
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
YT-TC-3 141.4 11.43 118.1 ND 29.22 ND
YCT-5 2.2 11.46 16.3 ND 200 10000
MLT-II-18 3.4 11.7 11 ND 225 10000
XHE-II-O53-ACID 50.35 11.8 44 ND 5.9 5000
SHU-1-19 4 12 7 48 14 84
RY-067 21 12 10 ND 0.37 42
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Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
DM-III-01 (C18H12N3O2Br) 5000 12 ND ND 4.73 5000
MLT-II-18 3.9 12.2 24.4 ND 210 10000
SH-053-2󸀠F 21.99 12.34 34.9 ND 0.671 ND
WYS13 C20H18N2O3 2.442 13 27.5 ND 163 5000
PWZ-085 4.86 13 8.5 ND 0.55 40
MMB-III-14 13 13 6.9 333 1.1 333
RY-061 17 13 6.7 ND 0.3 31
WZ-113 19.2 13.2 13.4 ND 11.5 300
YT-II-83 32.74 13.22 24.1 ND 3.548 ND
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
LJD-III-15E 1.93 14 19 ND 70.8 1000
YT-III-272 295.9 14.98 10.77 ND 103.3 ND
BCCt 0.72 15 18.9 ND 110.8 5000
XHE-II-006b 3.7 15 12 1897 144 1000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
MLT-II-34 7.04 15.95 22.3 ND 158 1000
MSA-IV-35 2.1 16 21 ND 995 3000
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PS-1-35 C23H22N5OBr ND 16.03 24.41 ND ND ND
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
YT-III-42 382.9 16.83 44.04 ND 9.77 ND
XHE-I-065 7.2 17 18 500 57 500
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
SH-I-047 1710 17.52 1222 ND 1519 ND
XLi343 C20H19ClN2OSi 6.375 17.71 ND ND 150.5 ND
XHE-II-002 8.3 18 13 3.9 1.5 11
YT-III-38 1461 18.21 14.63 ND 3999
JYI-72 (C22H21N4SiF) 48.5 18.5 ND ND 11.5 5000
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
JC208 C15H10N2OS 22.42 18.89 ND ND 5.039 ND
diazepam 14 20 15 ND 11 ND
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
included volume overlay that the 𝐿
2
pocket is deeper for the
𝛼5 subtype, as determined previously [13, 21–23, 110, 119].The
new 𝐿
4
pocket can be distinguished as the new yellow region
of the 𝛼5𝛽3𝛾2 subtype which is due to recently designed R-
isomers by Huang [135], Poe and Li.
17. The 𝛼6𝛽3𝛾2 Receptor Subtype
See Table 10 and Figures 46 and 47.
18. Updates to the Previous Model
In addition to the newly discovered 𝐿
4
pocket, the updated
library of binding affinity led to two specific updates in the
previous model (Figure 48).
19. QSAR
A nontraditional quantitative structure activity relationship
(QSAR) approach was executed to observe steric and electro-
static preferences for each receptor subtype. A subset of the
compounds used in each subtype pharmacophore/receptor
model were chosen with a good cross section of scaffold
variety. The compounds used in the COMFA maps are the
imidazobenzodiazepines published previously [110, 137] and
additionally alternative scaffolds which bound with <20 nM
at the respective subtype [22].
The interest here was in creation of steric and electrostatic
maps of the comparative molecular field analyses (COMFA)
created from molecular spreadsheets. A variety of com-
pounds selective for each subtype were selected and placed
into a dataset used to build the CoMFAmodels. Activities (𝐾
𝑖
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Table 7: Ligands with potent affinity for 𝛼3; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 ND 69.32 ND
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
QH-II-077 0.06 0.08 0.05 ND 0.12 4
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
XLI-286 0.051 0.064 0.118 ND 0.684 ND
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
JYI-57 0.076 0.076 0.131 ND 0.036 ND
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
PZII-028 0.2 ND 0.2 ND 0.32 1.9
QH-II-075 0.18 0.21 0.25 ND 1.3 40
JYI-42 0.257 0.146 0.278 ND 0.256 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
JYI-55 41.39 ND 0.504 ND 24.75 ND
JYI-47 2.759 2.282 0.511 ND 0.427 ND
DM-239 1.5 ND 0.53 ND 0.14 6.89
WY-B-15 0.92 0.83 0.58 2080 4.42 646
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
QH-146 0.49 ND 0.76 ND 7.7 10000
PZII-029 0.34 ND 0.79 ND 0.52 10
WYS19 C26H32N2O4Si ND ND 0.89 ND ND ND
XHE-III-06a 1 2 1 5 1.8 37
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
XHE-III-04 1.2 2 1.1 219 0.4 500
FG8205 0.4 2.08 1.16 ND 1.54 227
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
alprazolam 0.8 0.59 1.43 ND 1.54 10000
XLI-348 13.56 11.17 1.578 ND 82.05 ND
QH-II-082 1.7 1.8 1.6 ND 6.1 100
WY-TSC-4 (WYS8) 0.007 0.99 1.63 ND 51.04 ND
SPH-121 0.14 1.19 1.72 ND 4 479
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
6-PBC 0.49 1.21 2.2 ND 2.39 1343
YT-III-271 32.54 1.26 2.35 ND 103 ND
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
TG-II-82 1.6 2.9 2.8 ND 1 1000
OMB-18 3.9 1.2 3.4 1733 0.8 5
YT-II 6.932 0.8712 3.518 ND 5.119 ND
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Table 7: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
PS-1-34B C20H17N4BrO ND 4.198 3.928 ND ND ND
DMCM 5.69 8.29 4 ND 1.04 134
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
RY-008 3.75 7.2 4.14 ND 1.11 44.3
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
XLI-317 60.24 24.05 4.562 ND 0.295 ND
QH-II-080b 3 3.7 4.7 ND 24 1000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
BCCE 1.2 4.9 5.7 ND 26.8 2700
MMB-II-90 20 24 5.7 9 0.25 36
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
ZK 93423 4.1 4.2 6 ND 4.5 1000
RY-061 17 13 6.7 ND 0.3 31
JYI-54 (C24H15N3O3F4) 2.89 172 6.7 ND 57 1890
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
MMB-III-14 13 13 6.9 333 1.1 333
XHE-II-017 3.3 10 7 258 17 294
SHU-1-19 4 12 7 48 14 84
XHE-III-13 7.3 ND 7.1 880 1.6 311
DM-215 6.74 ND 7.42 ND 0.293 8.28
ABECARNIL 12.4 15.3 7.5 ND 6 1000
SVO-8-14 8 25 8 6.9 0.9 14
XHE-III-24 0.25 ND 8 222 10 328
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
PWZ-085 4.86 13 8.5 ND 0.55 40
XHE-I-093 2 7.1 8.9 1107 20 1162
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
RY-067 21 12 10 ND 0.37 42
XHE-III-14 2.6 ND 10 13 2 7
YT-III-272 295.9 14.98 10.77 ND 103.3 ND
SPH-38 2 5.4 10.8 ND 18.5 3000
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
MLT-II-18 3.4 11.7 11 ND 225 10000
DM-II-33 (C20H13N3O2BrCl3) 88.6 85 11.6 ND 26.2 5000
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
XHE-II-006b 3.7 15 12 1897 144 1000
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
CM-B44 (ss) 32 43 12 379 4.3 485
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Table 7: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
JYI-48 75.59 90.68 12.78 ND 31.28 ND
XHE-II-002 8.3 18 13 3.9 1.5 11
RY-076 26 27 13 ND 0.7 22
WZ-113 19.2 13.2 13.4 ND 11.5 300
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
CM-E10 23 26 14 215 0.51 96
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
YT-III-38 1461 18.21 14.63 ND 3999 ND
CM-A87 1.62 4.54 14.73 1000 4.61 1000
diazepam 14 20 15 ND 11 ND
RY-053 49 29 15 ND 1 46
YCT-5 2.2 11.46 16.3 ND 200 10000
RY-098 10.1 22.2 16.5 ND 1.68 100
PWZ-096 11.1 36 16.9 ND 1.07 51.5
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
XHE-I-065 7.2 17 18 500 57 500
SH-I-02B 29.82 1315 18 ND 74.05 ND
MLT-II-16 5.05 10.41 18.4 ND 260 10000
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
BCCt 0.72 15 18.9 ND 110.8 5000
LJD-III-15E 1.93 14 19 ND 70.8 1000
CM-E09b 20 22 19 55 0.45 69
RY-I-31 10 45 19 ND 6 1000
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
XHE-II-006a 4.7 4.4 20 1876 89 3531
OMB-19 22 4.6 20 3333 3.5 40
XHE-III-06b 32 33 20 299 28.6 740
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
values) were converted to logarithmic units for this study. A
CoMFA descriptor set was created based on the –log (𝐾
𝑖
) of
over 70 structures.The goal was to derive an alternative three-
dimensional shape of the receptor using biological activity of
the most selective compounds. Structures were determined
by crystal structurewhere available or by calculation. Charges
were provided based on the Gasteiger-Huckel model. Con-
formations were kept consistent based on previous studies of
low energy conformations [110]. It should be noted that this
was not a traditional QSAR study as nonselective compounds
were excluded. Therefore, 𝐾
𝑖
values did not cross 3 log
units. This was acceptable since the goal was not to create
a predictive QSAR predictive algorithm, rather a map of
the receptor based on sterics and electrostatics. Hydrogen
acceptor radii were set to 3.0 and the hydrogen donor radii
were set to 2.6 based on recommendations from Certara
(Tripos). Analyses were executed using PLS (partial least
squares). The details of modeling will be further discussed in
the SI.
For each of the following QSAR models (Figures 49–
64), green areas represent desirable steric bulk and yellow
represents undesirable steric bulk. Positive electrostatic con-
tributions are represented by blue and negative electrostatic
contributions are represented by red.
20. The 𝛼1𝛽3𝛾2 Receptor Subtype
See Figures 49–52.
21. The 𝛼2𝛽3𝛾2 Receptor Subtype
See Figures 53–56.
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Table 8: Ligands with potent affinity for 𝛼4; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in
the Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
XHE-III-74 77 105 38 0.42 2.2 5.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
XHE-II-002 8.3 18 13 3.9 1.5 11
XHE-III-06a 1 2 1 5 1.8 37
RY-080 C17H15N3O3 28.4 21.4 25.8 5.3 0.49 28.8
TG-4-39 1.6 34 24 5.6 1.4 23
SVO-8-14 8 25 8 6.9 0.9 14
RY-023 C22H27N3O3Si 197 142.6 255 7.8 2.61 58.6
MMB-II-90 20 24 5.7 9 0.25 36
XHE-III-14 2.6 10 13 2 7
XHE-II-024 0.09 0.18 0.32 14 0.24 11
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
SVO-8-67 7 41 26 15 2.3 191
CM-B31i (ss) 90 184 78 18 4.9 121
SVO-8-20 11 40 28 19 8.6 138
aAffinity of compounds atGABAA/BzR recombinant subtypeswasmeasured
by competition for [3H]flunitrazepamor [3H]Ro15-4513 binding toHEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average
of at least three determinations with a SEM of ±5%. ND: not determined.
22. The 𝛼3𝛽3𝛾2 Receptor Subtype
See Figures 57–60.
23. The 𝛼5𝛽3𝛾2 Receptor Subtype
From the CoMFA maps several observations (Figure 65) can
bemade.The yellow steric regions near 𝐿
3
in the 𝛼5𝛽3𝛾2map
are unique. This illustrated that, in general, benzodiazepines
lacking a pendant phenyl are more suited to targeting the 𝛼5
subtype.The 𝐿Di region of the 𝛼1 subtype is most tolerable for
compounds with steric interactions in this location while the
𝛼3 subtype receptor compounds prefer no steric interaction
in this location. Negative electrostatics are most preferred
by the 𝐿
3
pocket of the 𝛼2 and 𝛼5 receptors. In general,
the 𝛼1 subtype receptor prefers molecules without a dipole.
It should be noted that none of the analogs are ionic in
nature and the charges for this model were provided by the
Gasteiger-Huckel model. For this reason more emphasis is
placed on the steric relationships which exclude interactions
in the pharmacophores. In the future a QSAR study which
includes nonbinding benzodiazepines in the data set along
with activity data will permit the creation of a predictive
algorithm which will be very useful in lead targeting (see
Figures 61–65).
24. Conclusion
Benzodiazepines, 𝛽-carbolines, and other classes of com-
pounds readily target the GABAA receptors. The difficulty
is finding subtype selective ligands, since there is no crystal
structure of the Bz/GABAA-ergic site itself, just one com-
posed of five beta-subunits which has no Bz site to date.
The 𝛼5-BzR/GABAA subunit has recently been shown to be
important in the search to treat numerous cognition-based
illnesses including Alzheimer’s, schizophrenia, bipolar, and
depression, as well as more recently a bronchodilator, poten-
tially important in the treatment of asthma. As an inverse
agonist, PWZ-029 was able to counteract the memory-
impairing effects of scopolamine, a muscarinic antagonist,
in both object recognition tests and object retrieval tests in
rodents, and was active in primates, as well as samaritan
Alzheimer’s rats. The implications of these tests point to
a use as a possible treatment for Alzheimer’s disease. The
docking of PWZ-029 in the 𝛼5𝛾2 GABAAR-subunit details
the interactions between the pharmacophore/receptor model
binding site and this important negative allosteric modulator.
Furthermore, 𝛼5-BzR/GABAA positive allosteric modulator,
SH-053-2󸀠F-R-CH
3
, was shown to reverse deleterious effects
in the MAM-model of schizophrenia. The recent discovery
of 𝛼5-GABAAR in airway smooth muscle by Emala et al.





was found to be
effective in relaxing preconstricted airway smooth muscle,
as well as attenuating calcium-ion entry through the plasma
membrane. In addition, XLi-093 (an 𝛼5 receptor antagonist),
a potently binding 𝛼5-subtype selective bivalent ligand, has
been shown to inhibit the 𝛼5-cognition deficits effected by
diazepam and is a very good 𝛼5 benzodiazepine receptor site
antagonist. It has also been shown to reverse the effects of 𝛼5
PAMs and NAMs in both rodent and primate models. These
findings led to the exploration of the𝛼5-binding pocket in the
Milwaukee-based pharmacophore.
New features have been introduced to the unified phar-
macophore/receptor model based on many substance classes
that act at the diazepam sensitive and diazepam insensitive
BzR binding sites of GABAA receptors.Themajor new feature
identified for the 𝛼5𝛽3𝛾2 receptor was a new 𝐿
4
pocket which
was found by using pendant 6-phenyl benzodiazepines with
a R-CH
3
at the prochiral center at C4. Further enhance-
ment of potency was achieved by addition of 2󸀠-F or 2󸀠-N
substituent in the pendant phenyl ring at C-6. While these
changes have led to enhanced subtype selective ligands, the
overall development guided by this pharmacophore model
described here has led to new agents with varying, fascinating
pharmacological profiles, ranging from use in cognition-
based diseases such as Alzheimer’s and schizophrenia, to
use as a bronchodilator. This research on updating the
Milwaukee-based pharmacophore/receptor model can be
used in the rational design for improving the selectivity
of 𝛼5 ligands. As the library of compounds increases, the
data which follows can then be further evaluated and can
lead to more insight to the identification of the possible
roles each individual residue may have with the binding
pocket.
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Table 9: Ligands with potent affinity for 𝛼5; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
JYI-57 0.076 0.076 0.131 ND 0.036 ND
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
QH-II-077 0.06 0.08 0.05 ND 0.12 4
DM-239 1.5 ND 0.53 ND 0.14 6.89
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
SH-I-75 1487 989.9 773 ND 0.1825 ND
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
XHE-II-024 0.09 0.18 0.32 14 0.24 11
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
MMB-II-90 20 24 5.7 9 0.25 36
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
JYI-42 0.257 0.146 0.278 ND 0.256 ND
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
DM-215 6.74 ND 7.42 ND 0.293 8.28
XLI-317 60.24 24.05 4.562 ND 0.295 ND
RY-061 17 13 6.7 ND 0.3 31
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
PZII-028 0.2 ND 0.2 ND 0.32 1.9
RY-067 21 12 10 ND 0.37 42
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
XHE-III-04 1.2 2 1.1 219 0.4 500
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
JYI-47 2.759 2.282 0.511 ND 0.427 ND
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
CM-E09b 20 22 19 55 0.45 69
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
RY-080 C17H15N3O3 28.4 21.4 25.8 5.3 0.49 28.8
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
CM-E10 23 26 14 215 0.51 96
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PZII-029 0.34 ND 0.79 ND 0.52 10
PWZ-085 4.86 13 8.5 ND 0.55 40
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
ZG-63A 17.3 21.6 29.1 ND 0.65 4
SH-053-2󸀠F 21.99 12.34 34.9 ND 0.671 ND
XLI-286 0.051 0.064 0.118 ND 0.684 ND
SH-I-S66 22.93 30.36 55.26 ND 0.69 ND
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Table 9: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
RY-076 26 27 13 ND 0.7 22
DM-173 13.1 ND 38.1 ND 0.78 118
OMB-18 3.9 1.2 3.4 1733 0.8 5
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
SVO-8-14 8 25 8 6.9 0.9 14
JYI-03 (C21H21N3O3) 185.4 107 ND ND 0.954 3.34
TG-II-82 1.6 2.9 2.8 ND 1 1000
RY-053 49 29 15 ND 1 46
YT-6 15.31 87.8 60.49 ND 1.039 ND
DMCM 5.69 8.29 4 ND 1.04 134
PWZ-096 11.1 36 16.9 ND 1.07 51.5
MMB-III-14 13 13 6.9 333 1.1 333
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
RY-008 3.75 7.2 4.14 ND 1.11 44.3
XLI-2TC 3.442 1.673 44.08 ND 1.121 ND
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
QH-II-075 0.18 0.21 0.25 ND 1.3 40
RY-054 59 44 27 ND 1.3 126
TG-4-39 1.6 34 24 5.6 1.4 23
XHE-II-002 8.3 18 13 3.9 1.5 11
RY-031 (RY-10) 20.4 27 26.1 ND 1.5 176
FG8205 0.4 2.08 1.16 ND 1.54 227
alprazolam 0.8 0.59 1.43 ND 1.54 1000
XHE-III-13 7.3 ND 7.1 880 1.6 311
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
RY-098 10.1 22.2 16.5 ND 1.68 100
YT-5 0.421 0.6034 36.06 ND 1.695 ND
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
RY-033 14.8 56 25.3 ND 1.72 22.9
XHE-III-06a 1 2 1 5 1.8 37
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
XHE-III-14 2.6 ND 10 13 2 7
DM-II-72 (C15H10N20BrCl) 5000 1.37 ND ND 2.02 5000
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
XHE-III-74 77 105 38 0.42 2.2 5.8
SVO-8-67 7 41 26 15 2.3 191
6-PBC 0.49 1.21 2.2 ND 2.39 1343
RY-058 86 40 85 ND 2.4 150
ZG-224 17.1 33.7 50 ND 2.5 31.7
RY-066 83 60 48 ND 2.6 180
RY-023 C22H27N3O3Si 197 142.6 255 7.8 2.61 58.6
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
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Table 9: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
OMB-19 22 4.6 20 3333 3.5 40
ZG-213 12.8 49.8 30.2 ND 3.5 22.5
YT-II-83 32.74 13.22 24.1 ND 3.548 ND
RY-059 89 70 91 ND 3.7 301
SPH-121 0.14 1.19 1.72 ND 4 479
RY-047 200 124 79 ND 4 340
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
YT-I-38 945.9 326.8 245.9 ND 4.07 ND
DM-146 6.44 ND 148 ND 4.23 247
CM-B44 (ss) 32 43 12 379 4.3 485
CM-B47 32 63 34 2007 4.4 717
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
WY-B-15 0.92 0.83 0.58 2080 4.42 646
ZK 93423 4.1 4.2 6 ND 4.5 1000
JYI-12 (C19H16N3O3F3) 91 39 ND ND 4.5 6.8
CM-A87 1.62 4.54 14.73 1000 4.61 1000
DM-III-01 (C18H12N3O2Br) 5000 12 ND ND 4.73 5000
RY-057 73 85 97 ND 4.8 333
JYI-15 (C19H14N3O3F3) 205 812 ND ND 4.8 22
CM-B31i (ss) 90 184 78 18 4.9 121
RY-079 121.1 141.9 198.4 159 5 113.7
JC208 C15H10N2OS 22.42 18.89 ND ND 5.039 ND
YT-II 6.932 0.8712 3.518 ND 5.119 ND
XLi270 C19H14N4 36.39 25.81 ND ND 5.291 ND
XHE-I-051 35 39 42 ND 5.3 979
MMB-II-87 200 333 107 109 5.4 333
XLI-210 231 661 2666 ND 5.4 54.22
XHE-II-O53-ACID 50.35 11.8 44 ND 5.9 5000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
RY-I-31 10 45 19 ND 6 1000
QH-II-082 1.7 1.8 1.6 ND 6.1 100
SH-TSC-1 (PWZ-029) 362.4 180.3 328.2 ND 6.185 ND
XHE-II-065 1000 409 216 37 6.4 175
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
QH-II-066 76.3 42.1 47.4 2000 6.8 3000
XLI-381 619.9 285.6 3639 ND 7.051 ND
RY-071 19 56 91 ND 7.2 266
RY-I-28 283 318 102 ND 7.2 61
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
YT-III-31 36.39 67.85 129.7 ND 7.59 ND
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
QH-146 0.49 ND 0.76 ND 7.7 1000
QH-II-063 9.4 9.3 31 ND 7.7 3000
JC221 ANX1 106.175 49.405 182 ND 7.7495 362
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
SH-TS-CH
3
107.2 50.09 20.95 ND 8.068 ND
RY-073 156 88 122 ND 8.5 267
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Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SVO-8-20 11 40 28 19 8.6 138
SHU-221-1 66 41 43 3000 9 3000
YT-III-231 51.09 61.46 26.34 ND 9.124 ND
CM-E09a 176 192 122 490 9.2 718
DM-139 5.8 ND 169 ND 9.25 325
YT-III-42 382.9 16.83 44.04 ND 9.77 ND
CD-214 16.4 48.2 42.5 ND 9.8 168
XHE-III-24 0.25 ND 8 222 10 328
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
JYI-01 (C19H20N3O3Br) 59.2 159 96 ND 10.6 2.88
diazepam 14 20 15 ND 11 ND
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
WZ-113 19.2 13.2 13.4 ND 11.5 300
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
JYI-72 (C22H21N4SiF) 48.5 18.5 ND ND 11.5 5000
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
JYI-10 (C17H13N3O3F3Br) 5000 368 ND ND 12.3 23
WZ-069 40 30.5 38.5 ND 12.6 1000
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
RY-072 220 150 184 ND 12.7 361
JYI-14 (C17H14N3O3F3) 32 25 ND ND 13 565
XHE-II-053 287 45 96 1504 13.8 1000
Xli-347 C34H28N6O7 828.05 690.2 ND ND 13.87 ND
SHU-1-19 4 12 7 48 14 84
CM-C28 (SR) 176 752 244 290 14 141
CM-E11 333 308 161 394 14 750
XHE-II-012 49 24 31 1042 14 2038
MMB-III-018 117 140 78 3500 14 976
MMB-III-18 117 140 78 3500 14 976
CM-B31c (ss) 118 319 173 37 15 137
CM-B45 230 557 336 265 15 230
XLI-093 1000 1000 858 1550 15 2000
DM-II-20 (C22H14N3O2F3) 54.3 27.14 35.68 ND 15.35 5000
XLi269 C22H22N4Si 221.8 154.2 ND ND 15.51 ND
SH-O53-S-CH
3
-2󸀠F 350 141 1237 ND 16 5000
JYI-13 (C21H16N3O4F3) 5000 63.7 ND ND 16 8.38
CM-B34 472 451 223 114 17 175
XHE-II-017 3.3 10 7 258 17 294
JC222 C16H12N2OS 86.7 45.11 ND ND 17.63 ND
SPH-38 2 5.4 10.8 ND 18.5 3000
WZ-070 72.7 30.7 53.2 ND 18.6 300
RY-069 692 622 506 ND 19 1000
SH-053-2󸀠F-S-CH
3
468.2 33.27 291.5 ND 19.2 ND
XHE-I-093 2 7.1 8.9 1107 20 1162
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
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Table 10: Ligands with potent affinity for 𝛼6; ligands bound with𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in
the Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PZII-028 0.2 ND 0.2 ND 0.32 1.9
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
JYI-01 (C19H20N3O3Br) 59.2 159 96 ND 10.6 2.88
JYI-03 (C21H21N3O3) 185.4 107 ND ND 0.954 3.34
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
JYI-11 (C22H22N3O3F3Si) 5000 5000 ND ND 648 3.97
QH-II-077 0.06 0.08 0.05 ND 0.12 4
ZG-63A 17.3 21.6 29.1 ND 0.65 4
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
OMB-18 3.9 1.2 3.4 1733 0.8 5
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
XHE-III-74 77 105 38 0.42 2.2 5.8
JYI-12 (C19H16N3O3F3) 91 39 ND ND 4.5 6.8
DM-239 1.5 ND 0.53 ND 0.14 6.89
XHE-III-14 2.6 ND 10 13 2 7
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
DM-215 6.74 ND 7.42 ND 0.293 8.28
JYI-13 (C21H16N3O4F3) 5000 63.7 ND ND 16 8.38
CGS9895 0.21 ND ND ND ND 9.3
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
PZII-029 0.34 ND 0.79 ND 0.52 10
XHE-II-024 0.09 0.18 0.32 14 0.24 11
XHE-II-002 8.3 18 13 3.9 1.5 11
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
JYI-19 (C23H23N3O3S) 2.176 205 ND ND 34 12.7
SVO-8-14 8 25 8 6.9 0.9 14
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
WYS10 C14H9F3N2O2 0.88 36 25.6 ND 548.7 15.3
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
PWZ-0071 0.23 0.17 0.12 0.44 17.31
aThe affinity of compounds at GABAA/BzR recombinant subtypes was
measured by competition for [3H]flunitrazepam binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [139]. Data represent the average of
at least three determinations with a SEM of ±5%. ND: not determined.
The X-ray structure determination of the 𝛼5𝛽3𝛾2
GABA(A) receptor is eagerly awaited, while that with five
𝛽3-subunits has been reported recently (Miller and Aricescu,
Nature 2014). It is hoped that the proposed orientation may
be used by others to gain additional insight into the potential
mechanisms underlying binding and modulation at the Bz
site, all of which will lead to a better understanding of the
structure and function of GABA(A) receptors, ultimately
targeted toward treatment of diseases.
25. Synthesis of Ligands with
𝛼5 BzR Subtype Selectivity
Briefly, bromoacetyl bromide was added to 2-aminobenzo-
phenone 44, followed by treatment with methanol, which
had been saturated with ammonia (g) under the cooling
of an ice-water bath. The benzodiazepine, 45, was bromi-
nated to provide 46 and then reacted with ethyl iso-
cyanoacetate to generate the imidazobenzodiazepine, 47. A
much better one-pot process has now been devised using
KtBuO at −30∘C [140]. The bromide 48 was subjected
to a Stille-type coupling to give DM-I-81 (9) [126]. This
route (Scheme 1) can be executed on several hundred gram
scales.
The benzodiazepine monomers were prepared by the
method of Fryer and Gu [89, 141]. The isatoic anhydride was
heated with sarcosine in dimethyl sulfoxide to provide amide
49. Bromination of 49 in a mixture of acetic acid, bromine,
and sodium acetate afforded the corresponding monosubsti-
tuted bromide 50 in good yield. Deprotonation of 50 with
lithium diisopropyl amide (LDA) in THF was followed by
treatment with diethyl chlorophosphate to provide the inter-
mediate enol phosphate.The enol phosphate was stirred with
a solution of ethyl isocyanoacetate and LDA to yield the imi-
dazo congener. Again, a better one-pot procedure has been
developed using KtBuO at −30∘C in place of LDA at 0∘C. A
Heck type coupling reaction was employed with the bromide
51 with bis(acetate)bis(triphenylphosphine)palladium(II) to
provide the TMS-acetylene 52. Treatment of 52 with Bu
4
NF
removed the trimethylsilyl group. Hydrolysis of the ester
function of 53 provided the acid 54 in excellent yield and this
material was dried scrupulously and subjected to a standard
CDI-mediated coupling reaction to furnish bivalent ligand
XLi-093 (4).The imidazobenzodiazepine diethyl diester XLi-
356 (10) was obtained from XLi-093 (Scheme 2) in high yield
via catalytic hydrogenation (Pd/C, H
2
).
26. Synthesis of Bivalents
Inverse agonist 53 was synthesized via the reported proce-
dure. Hydrolysis of the ester function of 53 provided the acid
54 in excellent yield. This material was dried scrupulously
and was subjected to a standard CDI-mediated coupling
reaction to furnish bivalent ligands 4, 55, and 56 in 60% yield
(Scheme 3) [13].
The acid 57, obtained from the ester 47, which was
available from the literature [13], was stirred with CDI
in DMF, followed by stirring with the required diol and
DBU to provide bromide substituted dimers 58 or 59,
respectively. They were converted into the trimethylsily-
lacetylenyl 60 or 61, respectively, under standard conditions
(Pd-mediated, Heck-type coupling) [142]. The bisacetylene
62 or63 (individually) was easily obtained by treatment of the
trimethylsilyl ligand 60 or 61with fluoride anion, as shown in
Scheme 4.
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Figure 34: Overlay of selected compounds for 𝛼1𝛽3𝛾2 subtype from
Table 5.
Figure 35: Updated 𝛼1𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 36: Overlay of compounds selective for 𝛼2𝛽3𝛾2 subtype.
Figure 37: Updated 𝛼2𝛽3𝛾2 subtype (solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 38: Overlay of compounds selective for 𝛼3𝛽3𝛾2 subtype.
Figure 39: Updated 𝛼3𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 40: Overlay of selected compounds selective for 𝛼4𝛽3𝛾2
subtype.
Figure 41: Updated 𝛼4𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (yellow wire). Overlap identified where wire and
solid overlap.
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Figure 42: Overlay of selected compounds selective for 𝛼5𝛽3𝛾2
subtype.
L4
Figure 43: Updated 𝛼5𝛽3𝛾2 subtype (blue solid) overlaid with the








Figure 44: Overlay of the 𝛼5𝛽3𝛾2 receptor (yellow) subtype with
the 𝛼1𝛽3𝛾2 receptor (magenta) subtype. Orange surfaces indicate
overlapping regions.
27. Materials, Methods, and Experimental
27.1. Materials and General Instrumentation. Chemicals were
purchased from Aldrich Chemical Co. or Tokyo Chemical
Industries and were used without further purification except
where otherwise noted. Anhydrous THF was distilled from
sodium/benzophenone ketyl. TLC analyses were carried out
on Merck Kieselgel 60 F
254
, and flash column chromatog-
raphy was performed on silica gel 60b purchased from
E. M. Laboratories. Melting points were taken on a Thomas-
Hoover melting point apparatus or an Electrothermal Model
IA8100 digital melting point apparatus and are reported
uncorrected. NMR spectra were recorded on a Bruker 300
or 500MHz multiple-probe spectrometer. Infrared spectra
were recorded on a Nicolet DX FTIR BX V5.07 spectrometer
or a Mattson Polaris IR-10400 instrument. Low-resolution
mass spectral data (EI/CI) were obtained on a Hewlett-
Packard 5985B GC-mass spectrometer, while high resolution
mass spectral data were taken on a VG autospectrometer
(Double Focusing High Resolution GC/Mass Spectrometer,
UK).Microanalyseswere performed on aCEElantech EA1110
elemental analyzer. Methods of specific experiments can be
found in corresponding cited works.
27.2. Competition Binding Assays. Competition binding
assays were performed in a total volume of 0.5mL of a
50mM Tris-acetate at 4∘ degree centigrade for 1 hour using
[3H]flunitrazepam as the radioligand. For these binding
assays, 20–50mg of membrane protein harvested with
hypotonic buffer (50mM Tris-acetate pH 7.4 at 4 degree)
was incubated with the radiolabel as previously described
[139, 143]. Nonspecific binding was defined as radioactivity
bound in the presence of 100 𝜇M diazepam and represented
less than 20% of total binding. Membranes were harvested
with a Brandel cell harvester followed by three ice-cold
washes onto polyethyleneimine-pretreated (0.3%) Whatman
GF/C filters. Filters were dried overnight and then soaked in
Ecoscint A liquid scintillation cocktail (National Diagnostics;
Atlanta, GA). Bound radioactivity was quantified by liquid
scintillation counting. Membrane protein concentrations
were determined using an assay kit from Bio-Rad (Hercules,
CA) with bovine serum albumin as the standard.
27.3. Radioligand Binding Assays (Drs. McKernan and Atack)
[12]. In brief, the affinity of compounds for human recom-
binant GABA(A) receptors was measured by competition
binding using 0.5 nM [3H]flunitrazepam. Transfected HEK
cells (beta2 gamma2 and desired alpha subtype) were har-
vested into phosphate-buffered saline, centrifuged at 3,000 g,
and stored at −70∘C until required. On the day of the assay,
pellets were thawed and resuspended in sufficient volume of
50mM Tris/acetate (pH 7.4 at 4∘C) to give a total binding
of approximately 1500–2000 dpm. Nonspecific binding was
defined in the presence of 100mM (final concentration)
diazepam. Test compounds were dissolved in DMSO at a
concentration of 10mM and diluted in assay buffer to give
an appropriate concentration range in the assay, such that the
final DMSO concentration in the assay was always less than
1%. Total assay volume was 0.5mL and assays were carried
out in 96-well plates and incubation time started by the
addition of 0.1mL of resuspended cell membranes. Following
incubation for 1 hour at 4∘C, assays were terminated by
filtration through GF/B filters, washed with 10mL ice cold
buffer, dried, and then counted using a liquid scintillation
counter. The percentage of inhibition of [3H]flunitrazepam
binding, the IC
50
, and the 𝐾
𝑖
values were calculated using
the Activity Base Software Package (ID Business Solutions,
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Figure 45: Overlay of the 𝛼5𝛽3𝛾2 receptor (yellow) subtype with the 𝛼1𝛽3𝛾2 receptor (magenta) subtype (Figure 44 rotated 90∘). Orange
surfaces indicate overlapping regions.
Figure 46: Overlay of selected compounds selective for 𝛼6𝛽3𝛾2 subtype.
Figure 47: Updated 𝛼6𝛽3𝛾2 subtype (blue solid) overlaid with the previous model (yellow wire). Overlap identified where wire and solid
overlap.
Guildford, UK) according to the Cheng-Prusoff equation
[143]. We have previously reported the synthesis of the
following.
1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 4
(XLi-093) (Procedure A), experimental details previously
reported [17].
1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) pentyl diester 56
(XLi-210), experimental details previously reported [17].








(a) Orthogonal views of the overlap (yellow) volumes









(b) Orthogonal views of the overlap (yellow) volumes







(c) Orthogonal views of the overlap (yellow) volumes








(d) Orthogonal views of the overlap (yellow) volumes of







(e) Orthogonal views of the overlap (yellow) volumes
of 𝛼5𝛽3𝛾2 (red) and 𝛼1𝛽3𝛾2 (green)
(f) Diazepam and the unified
pharmacophore descriptors
Figure 48:The previous benzodiazepine subtype selective receptor pharmacophore models [23]. (1)The 𝐿
2
region in the 𝛼5 subtype is larger
than the 𝛼1 subtypes. This is a key result. It is the principle difference between 𝛼5 subtypes compared to 𝛼2 and 𝛼3 subtypes, but especially in
regard to 𝛼1 subtypes (𝐿
2
smaller in 𝛼1). (2) The 𝐿
3
region is larger in the 𝛼5 subtype as compared to the 𝛼1, 𝛼2, 𝛼3, 𝛼4, and 𝛼6 BzR sites. R
analogs of benzodiazepines with pendant phenyls had increased affinity to 𝛼5 supporting the larger 𝐿
3
pocket in this receptor subtype, while
S isomers bound to 𝛼2, 𝛼3, and 𝛼5 subtypes because of different conformational constraints.
Figure 49: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
1,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 10
(Xli-356), experimental previously published [144].
Figure 50: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective (Figure 45) rotated 90∘.
Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) dimethyl glycol dies-
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Figure 51: Steric (left) and electrostatic maps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
Figure 52: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective
rotated 90∘.
Figure 53: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
Figure 54: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
ter 55 (Xli-374), experimental details previously reported
[17].
8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diaze-
pine-3-carboxylic acid 57, experimental details previously
reported [17].
Figure 55: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
Figure 56: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective
rotated 90∘.
Figure 57: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
Figure 58: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
Figure 59: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
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Figure 60: Steric (left) and electrostatic maps of the 𝛼3𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective rotated
90∘.
Figure 61: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in the transparent mode as seen from the classic
perspective.
Figure 62: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
Figure 63: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective.
Figure 64: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective rotated
90∘.
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Scheme 1: Synthesis of 8-substituted imidazobenzodiazepines following chemistry earlier developed by Sternbach, Fryer et al. Reagents and
Conditions. (a) Bromoacetyl bromide, sodium bicarbonate, and chloroform; (b) ammonia (anhydrous), methanol, and reflux; (c) bromine,
sulfuric acid, and acetic acid; (d) sodium hydride, diethyl chlorophosphate, and tetrahydrofuran; (e) sodium hydride, ethyl isocyanoacetate,






a][1,4]diazepine-3-carboxy) propyl diester 59 (DMH-D-070)
(Procedure B), experimental details previously reported [17].
1,3-Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-ben-
zo[f]imidazo[1,5-a][1,4]-diazepine-3-carboxy) propyl diester
61 (DMH-D-048) (Procedure C), experimental details
previously reported [17].
1,3-Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxy) propyl diester 63 (DMH-D-053):
experimental details previously reported [17].
Bis(8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]di-
azepine-3-carboxy) diethylene glycol diester 58 (DM-III-93),
experimental details previously reported [17].
Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-benzo[f]imid-
azo[1,5-a][1,4]diazepine-3-carboxy) diethylene glycol diester
60 (DM-III-94), experimental details previously reported
[17].
Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxy) diethylene glycol diester 62
(DM-III-96), experimental details previously reported [17].
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Scheme 2: Synthesis of 8-substituted imidazobenzodiazepine bivalent ligands. Reagents and Conditions. (a) DMSO, 180∘C, 90%; (b) bromine,







, triethylamine, acetonitrile, and reflux, 80%; (f) tetrabutylammonium fluoride, THF, and H
2
O, r.t.,




OH, and DBU, 60%; (i) Pd/C, H
2




























, 4 , 55 CX = CH2 X = 0 X = CH2 H2CH2, 56
Scheme 3: Synthesis of bivalent analogs of XLi-093 (4). Reagents and Conditions. (a) 2MNaOH, EtOH, 70∘C; (b) 10% aq HCl; (c) CDI, DMF;
(d) diol, DBU.


































































Scheme 4: Synthesis of bivalent analogues of DMH-D-053 (63). Reagents and Conditions. (a) 2N NaOH, EtOH, and reflux; (b) 10% aq. HCl;










CN, and reflux; (f) TBAF∗0.5H
2
O, THF, −78∘C.
GABA: Gamma amino butyric acid
GABAA: Gamma amino butyric acid A
GABAAR: Gamma amino butyric acid A receptor
HAL: Haloperidol
HEK: Human embryonic kidney
HPC: Hippocampal
LTK: Leukocyte tyrosine kinase
MAM: Methylazoxymethanol
NAM: Negative allosteric modulator
QSAR: Quantitative structure-activity relationship





SMA: Smooth muscle actin
TTX: Tetrodotoxin
VTA: Ventral tegmental area.
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